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Introduction 
 Try not to know all the answers, 
 but to understand all the questions.  (Eastern proverb)     
On Thursday April 29, 1869, in The Boston Medical and Surgical Journal,  
dr. George Beard, neurologist and lecturer on nervous diseases in the University of 
New York, published an “Original Communication” with the headline 
“Neurasthenia, or Nervous Exhaustion”17. This was the starting point of a history of 
chronic fatigue that has been and still is chronically intriguing - and confusing. 
George Beard is quoted to have said; “Fatigue is the Central Africa of medicine, an 
unexplored territory which few men enter”. 
I have had the fortune to enter this territory and have done so with interest and a 
sincere wish of exploring this exciting field of medicine.  After many years as a 
clinician and consultant in psychiatry, my professional interests focused gradually 
more on psychosomatics and stress medicine, and the illnesses of chronic fatigue 
seemed particularly fascinating. When meeting with professor Holger Ursin nearly 10 
years ago, having invited myself to discuss a possible minor research project on stress 
and chronic fatigue in a sabbatical period (-“there is no minor research except 
research being performed by minor researchers”), a minor suddenly became major, 
and there I was – on a long and winding road to systematic research and doctoral 
thesis – and here I am now. 
A major source of motivation has been the professional interest and wish to explore 
and understand. As important has been recognizing the need of knowledge and 
competence in this field, to meet and treat patients in need.  
If any supreme goal for this work, it has been to contribute to improving the 
competence and care in meeting patients with chronic fatigue.   
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Abstract 
Chronic fatigue syndrome (CFS) has been known as “neurasthenia” for more than 
hundred years and is today often called ME (myalgic encephalopathy), CFS/ME. The 
illness is characterized by excessive, prolonged and disabling fatigue, pain and 
somatic complaints, with functional and mental impairment and with major 
consequences in occupational and social life. Several case definitions with varying 
criteria are used for CFS. The prevalence is 0.5 % in a general population; the 
average length of the illness is more than 5 years, and rate of work disability is high. 
Prognosis is varying; few patients recover totally, but most patients improve 
substantially over 2-5 years. 
The objectives in this thesis were to investigate a clinical population with 
neurasthenia and chronic fatigue syndrome, by assessing subjective health 
complaints, functional impairment and work disability, by examining treatment 
effects of specific interventions, by studying long-term illness course and by 
analyzing the comorbidity of depression and personality patterns. 
 72 patients with ‘neurasthenia’ were compared with a reference population of 1000 
patients in general practitioners’ waiting-rooms. Patients with neurasthenia had more 
prevalent and more severe subjective health complaints than the reference population 
of patients, longer periods of sick leave and higher rates of work disability.  
The patients with neurasthenia/ CFS went through a 6 months randomised clinical 
trial of mirtazapine, placebo and a comprehensive cognitive-behavioural intervention 
(CCBT) program of CBT, body awareness therapy and graded exercise. By 3 months 
the CCBT program had better effect on fatigue symptoms and clinical global severity 
than mirtazapine medication or placebo alone. By combining the interventions, the 
combination of CCBT followed by mirtazapine had significantly better effect on 
fatigue severity by 6 months than placebo or the opposite sequence of initial 
medication followed by CCBT. Generally, the whole group with neurasthenia and 
CFS showed substantial clinical improvement after the treatment interventions. 
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In a 5 years follow-up study of this patient group, half of the patients reported a 
substantial reduction in fatigue symptoms, and diagnoses tended to shift from CFS 
towards neurasthenia and unspecific chronic fatigue during the follow-up period. 
Sudden onset, severity of fatigue at the initial phase of illness and slow improvement 
predicted a poor prognosis. Long-term course seemed more dependent of illness 
characteristics than of time-limited treatment interventions. 
The prevalence of personality disorders was found equal to non-clinical populations 
(13%) in CFS patients; the mean personality score was at an average level, indicating 
low general personality pathology. CFS patients had a clinical personality profile 
similar to that of somatoform disorder, with elevated scores of somatisation and 
health concerns and low scores of self-esteem and perfectionism.  
The findings in this thesis support the view of CFS as a severe illness with extensive 
health complaints and severe impairment. The findings also indicate that psychiatric 
symptoms and personality disorders are low in CFS. Although the prognosis of a full 
recovery in CFS seems poor, the effect of a comprehensive treatment intervention is 
generally good, and most patients improve gradually. 
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1. Introduction, background  
1.1 Fatigue, chronic fatigue  
and Chronic Fatigue Syndrome (CFS) 
 
1.1.1 The concept of Fatigue 
Although widely used and convenient both in everyday life and in medical 
descriptions, fatigue is a problematic concept, in the sense that a strict or precise 
definition is very difficult. Most people “know” what it means, but the meaning of the 
term is still vague and difficult to operationalize. Fatigue is essentially a subjective 
experience, and is difficult to separate from normal experiences of tiredness, 
sleepiness, overstrain or exercise exhaustion. The symptom of fatigue could be 
described as a pervasive sense of tiredness or lack of energy that is not related 
exclusively to exertion 164. This type of fatigue is not alleviated by rest and must be 
distinguished from weakness, malaise and temporary tiredness that occur as a direct 
result of excessive physical or mental exertion. In order to qualify fatigue as 
pathological, many researchers have described the subjective experience of fatigue as 
a continuum rather than a categorical entity 205,206,249. Although no clear cutoff exists 
between normal and abnormal fatigue, assessment using unique qualifiers may help 
distinguish between severity and duration of fatigue illness. Many attempts have been 
made to develop such qualifiers in defining and assessing fatigue 76,277.   The nature 
of fatigue still remains complex, comprising clearly different components and wide 
dimensions. A comprehensive analysis of fatigue 249 shows the need for considering 
fatigue in terms of a number of components, the principals being fatigue as 
behaviour, fatigue as a feeling, and fatigue as an internal state or mechanism, in 
addition to which the environment of the fatigued person and the demands upon them 
must always be specified.  
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Table 1: The dimensions of fatigue  
Fatigue is described by six different dimensions, each with several 
components that can express, explain, influence or measure fatigue. 
Behaviour e.g. work-out, endurance, relation to rest 
Feeling state Mental or physical; severity and quality 
Affective and evaluative pleasant/ unpleasant, anxiety/ depression 
Cognitive/ motivational e.g. enthusiasm, aversion 
Mechanism physiology, biochemistry, psychology 
Context physical factors: temperature and noise; 
social stressors; cultural context 
( adapted from Wessely, Hotopf, Sharpe: Chronic Fatigue and its syndromes) 249 
 
1.1.2 Chronic fatigue and Chronic Fatigue Syndrome 
Most clinicians and researchers distinguish normal fatigue and prolonged fatigue 
from both chronic fatigue and Chronic Fatigue Syndrome (CFS) 205. Prolonged 
fatigue is often defined as disabling fatigue that lasts at least one month. If this degree 
of fatigue is persisting and lasts more than 6 months, it is called chronic. Since there 
is no common standard for measurements of such fatigue or cutoff for normal/ 
pathological fatigue, chronic fatigue cannot be more clearly defined.  Depending on 
the specific case definition, a disabling and chronic fatigue condition is considered 
CFS if fulfilling specific criteria or case definitions 11,15,126,164,196, see Appendices: 
Case definitions (chapter 8.1). Yet, many clinicians and researchers argue that fatigue 
as a clear-cut symptom is not necessarily a sine qua non for the CFS illness, since 
accompanying symptoms like cognitive dysfunctions, general malaise and functional 
impairment are as essential elements of the illness as fatigue itself 38,187. 
The descriptions and dilemmas of case definitions are elaborated and discussed 
further in chapter 1.2.5 in this thesis. 
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1.1.3 The history of fatigue  
Fatigue is an old term for the condition of weakness, tiredness and lack of energy, 
being described through history, both in ancient stories and saga-telling and in 
literature and medical records 211. It has been described both as a symptom of or 
accompanying another medical condition, like infections, wounds and cancer, as well 
as psychological conditions like trauma or bereavement reactions. The Icelandic saga 
historian Snorre Sturlason (1179-1241) described states of fatigue in the Viking era 
more than thousand years ago, both as an exhaustion reaction after war and use of 
weapons 221,222 and as a bereavement reaction in the ancient Egil’s saga 97. 
People in the seventeenth century referred to an illness called “the vapors”, 
characterized by great fatigue and ill-explained general malaise. As early as 1698, 
John Pechey (London 1698) 175 described “vapors” as the "most frequent of all 
Chronical Diseases"… "wonderfully various that they resemble almost all the 
Diseases poor Mortals are subject to".  Vapors, he points out, affect all parts of the 
body, especially the back.  
One of the earliest medical descriptions was from the English physician, Sir Richard 
Manningham, who in a textbook in 1750 described symptoms of a disease he called 
“febricula”, or “little fever”, which sound similar to what we today call CFS 71. The 
illness presented with a profound sense of lassitude, accompanied by a bewildering 
variety of constitutional complaints, but few objective, clinical findings: “The 
symptoms of the febricula, or little, low, continued fever are these…transient 
chilliness…a mist before the eyes, listlessness, with great lassitude and weariness all 
over the body…little flying pain… and sometimes the patient is a little delirious and 
forgetful…” (Manningham 1750)72. 
Manningham also noted the association of this condition with stressful life events. 
“Febricula” never got a medical recognition, but the condition never disappeared… 
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The rise and fall of Neurasthenia 
The modern history of fatigue started in 1869, when the term and diagnosis 
neurasthenia was introduced in medical literature for the first time, both by the 
neurologist George Beard 17 and even earlier by the psychiatrist van Deusen 236. 
Beard was the one to be recognized for the description of the term, and it created a 
new paradigm of fatigue illness, as unexplained and mysterious fatigue suddenly got 
its physiological explanation, in Beard’s elaboration of neurasthenia. The somatic 
explanation offered was “nerve weakness” based on a “hypersensitivity” of the 
nervous system, in accordance with contemporary neurological state-of-knowledge 17. 
Beard himself was convinced that the causal aetiology of this illness was to be found 
in pathophysiological processes in the central nervous system (CNS): 
..the central nervous system becomes dephosphorized, or, perhaps, loses somewhat of 
its solid constituents; probably also undergoes slight, undetectable, morbid changes 
in its chemical structure, and, as a consequence, becomes more or less impoverished  
in the quantity and quality of its nervous force” (Beard, 1869). 
With no medical evidence to support his theory, some cautiousness seemed needed: 
..”I admit that this view is speculative, but I feel assured that it will in time be 
substantially confirmed by microscopical and chemical examinations of those 
patients who die in a neurasthenic condition”. 
Neurasthenia soon proved to be a much needed and attractive explanation for 
unexplained – and often ill-defined – conditions in its time. Throughout the next 
decades, the use of the term and by definition the prevalence of Neurasthenia 
increased almost epidemically 212.  
Four different uses of the term emerged during the late 1800’s 211: 
First, and mainly, neurasthenia was chronic fatigue. Chronic fatigue was and 
remained being the primary or “essential” symptom in neurasthenia, its “cardinal 
characteristics being an inordinate sense of physical or mental fatigue”.                
The manifestations of neurasthenia most often described was “neuromuscular 
Chronic Fatigue Syndrome: health and impairment, treatment and prognosis 21 
weakness” or …“unusually rapid exhaustion mainly affects the mental activities; the 
power of attention becomes quickly exhausted and the capacity for perception is 
paralysed 249.  Fatigue in neurasthenia was not relieved by rest. Patients with 
neurasthenia were “speedily exhausted in the process of moderate exercise”, 
and…”prolonged and severe mental effort” was equally impaired 249. 
Studying these and many other quotations from that time clearly indicates that 
neurasthenia was directly comparable to modern descriptions of chronic fatigue 
syndrome. It seems relevant to bear this in mind when discussing the contemporary 
questions concerning classification and differentiation of fatigue illnesses. 
The second aspect was the equation of neurasthenia with depression or mild 
melancholia. Overlapping symptoms like lack of energy, reduced activity, mental 
fatigability and sleep disturbances, and the absence of diagnostic criteria, made the 
distinction between neurasthenia and melancholia difficult. This is still the case 67.  
A third tradition for the use of neurasthenia was the neurasthenic symptoms in men 
under “stress”, mainly in working-class males in farming or industrial labour 211. At 
that time, neurasthenia in this sense was considered a male equivalent to female 
hysteria, and many clinicians and researchers considered these the same disorder, 
with the mechanism of irritability supposed to underlie both. Some physicians 
interested in social reform began from 1890 on diagnosing neurasthenia among 
working-class men whose health complaints until those days had been considered 
non-medical and which had been offered no medical care. This represented a way of 
“medicalizing” these people and their complaints, often representing somatoform 
complaints caused by “stress”, overload and poverty 211. This approach and use of 
“neurasthenia” directed for the first time medical attention to psychosomatic 
symptoms in men and provided explanations for stress-related exhaustion. It seems 
fair to say that modern concepts of burnout and 21st-century’s models of exhaustion 
depression 18,78,147 are in debt and display close resemblance to this concept and use of 
neurasthenia more than a hundred years ago.  
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The fourth main tradition in using the term neurasthenia was to see it as a synonym 
for general nervousness and evolving psychosis, a mixture of mood disorders, anxiety 
disorders and obsessive-compulsive disorders, combined with somatoform 
symptoms. It gradually became synonymous with “pan-nervousness”, which was a 
term so wide as to include anything and differentiate nearly nothing. Descriptions of 
neurasthenia as ”… a diagnostic wastebasket”  and “…a mob of incoherent 
symptoms borrowed from the most diverse disorders” 211 served to undermine its 
legitimacy. 
The  diagnosis came to be used quite liberally, to cover a multitude of obscure 
nervous affections of the most varied and opposing character 193. From being a 
popular diagnosis both to patients and physicians, the popularity of neurasthenia 
gradually decreased by the turn of the 19th century, both because of this diversity and 
incoherence in use of the diagnosis, and because it no longer offered the comfort of 
an acceptable diagnosis for unexplainable symptoms. Also, the development of 
medical knowledge created increasing discomfort with Beard’s increasingly archaic 
model of “deficiency of nervous strength”, which was found over-simplistic in 
absence of explanations of potential disturbances in the neural substrate 72. There was 
also an increasing awareness of the psychological aspects of behavioural antecedents 
of neurasthenia and the sequelae of the condition. Pierre Janet (1903) introduced 
Psychasthenia, whose main core was obsessive-compulsive states. Psychiatry rising 
as a medical discipline of its own also incorporated some of the conditions within the 
neurasthenia spectrum, especially the “neurotic” depression, and left neurasthenia 
with only the ill-defined and unexplained fatigue. The fall of Beard’s neurasthenia 
was dramatic. 
Although declining in popularity and prevalence, neurasthenia still continued to be 
used throughout the 20th century, mainly with the connotations of unexplained 
chronic fatigue accompanied by various somatic complaints. Internationally, 
neurasthenia certainly survived, and it is still an official diagnosis in the WHO 
International Classification of Diseases (ICD-10 – 10th edition)264. In 1999, The 
World Psychiatric Association (WPA) had an international group of psychiatrists 
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examining the use and meaning of neurasthenia throughout the world, and  a 
consensus report and statement was made concerning the relevance and usefulness of 
the term 266. The main conclusion was that neurasthenia was still alive. 
The criteria for the diagnosis of neurasthenia in ICD-10 265 are: either persistent and 
distressing complaints of feelings of exhaustion after minor mental effort or of fatigue 
and bodily weakness after minor physical effort, accompanied by one or more of the 
following symptoms: muscular aches and pains; dizziness; tension headaches; sleep 
disturbance; inability to relax; and irritability. There should be an inability to recover 
trough rest, relaxation or entertainment; the duration should exceed 3 months, and 
there should be no organic mental disorder, affective disorder, panic disorder or 
generalized anxiety disorder. 
Many researchers have advocated the revival of neurasthenia for clinical use, 
although the battle of terminology in the Western world since long seems lost to 
chronic fatigue syndrome (CFS) 115,244,253,272. Other researchers have pointed out that 
though neurasthenia seemed to disappear, the clinical conditions and disorders which 
it comprised still exist, and reappear in new terms and diagnoses, often with 
psychological labels 225. 
 
Chronic fatigue syndrome, CFS 
Having abandoned the model of constitutional and unexplained nervous weakness, 
there was from late 1800’s a search for medical explanations corresponding to 
contemporary medical knowledge. Already in the early 1900s, the concept that 
chronic fatigue could follow infections, such as influenza and typhoid, was 
established and widely accepted 249. The mechanisms by which an infection could 
produce post-infectious prolonged fatigue, was still mysterious. 
During the twentieth century, several outbreaks of fatigue with unknown aetiology as 
an principal symptom were reported 72,211,249, all together more than 60 reports, with 
varying quality in their descriptions 148. One of the first to be reported, and one to 
                       Bjarte Stubhaug 24 
serve as a template for later explanations of chronic fatigue, was the occurrence in the 
1930’s of brucellosis, or undulant/ Mediterranean fever. It is a bacterial infection 
spreading from animals to humans, with characteristics signs of an infection, like 
high fever, aches and pains, chills and malaise. Long-lasting fatigue following 
brucellosis was called chronic brucellosis, and the infection served as an accepted 
explanation for the chronic fatigue, even for some people who had never been 
infected but had all the symptoms, like muscular aches and pains, fatigue, irritability 
and mild depression. 
Chronic brucellosis illustrated dilemmas and unresolved questions highly relevant 
even today. Is the persisting fatigue a result of the obvious infection; is it caused by 
an simultaneous occult infection being precipitated by the first; is it due to possible 
postinfectious mechanisms (a concept that developed later); could it be an expression 
and symptom of psychiatric disorders like depression – having fatigue as a common 
symptom - or could it be seen as somatisation of psychological complaints, 
attributing the cause of fatigue to a somatic disease? 
Chronic brucellosis came to be used in the 1940’s and 50’s as a label for ill-defined 
fatigue and somatoform and somatising illness, but it never became a wide-spread or 
fashionable illness, sharing its destiny with theories of chronic fatigue that appeared 
and disappeared in the decades to follow, like reactive hypoglycaemia in the 1960’s, 
total allergy syndrome and chronic candidiasis of the 1970’s. Only by the rediscovery 
of infectious and post-infectious mechanisms and the distribution of information 
through modern media did the mysterious fatigue illness start to rise like neurasthenia 
once did 249. 
Epidemic outbreaks of mysterious fatigue were reported from the 1930’s, the first in 
1934 in Los Angeles General Hospital, among the employees at the hospital. It was 
labelled neuromyasthenia, muscle weakness caused by neurological pathology - 
presumed to be an atypical poliomyelitis infection. Other labels to be used were 
Icelandic (or Akureyri) disease – due to the local occurrence in Iceland - atypical 
poliomyelitis, or myalgic encephalomyelitis. The latter was coined in 1956 after an 
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outbreak of endemic fatigue among the nursing and medical staff in Royal Free 
Hospital in London in 1955 183. The term myalgic encephalomyelitis (ME) came to be 
the standard label in the public and patient groups in England in the years to follow. 
In USA, there were also several reports of similar outbreaks of epidemic fatigue 23,148, 
although few are described in detail. The label of neuromyasthenia came to be the 
dominating term in USA, with a clear assumption of a causal nervous infection. 
In 1984, in Lake Tahoe, Nevada, USA, and its surrounding communities, a severe 
outbreak of fatigue illness was reported 13. The symptoms of the Lake Tahoe outbreak 
included prolonged fatigue, abrupt onset of symptoms, severe pain and prominent 
cognitive disorder 148. In many patients affected at Lake Tahoe, Epstein-Barr virus 
(EBV) antibodies were detected, and a causal explanation of definite organicity by 
post-infectious mechanisms was claimed. After this outbreak, the term Chronic 
Epstein-Barr Virus infection fatigue was being used, soon to be renamed as post-viral 
chronic fatigue syndrome or just chronic fatigue syndrome, CFS, with the addition in 
the US of a “immune deficiency” syndrome, CFIDS. 
By the late 1980’s, the illness of severe and prolonged fatigue was being known to 
the public, and there was an increasing pressure on the medical authorities to 
recognize the illness as an entity of it own. In 1988, the Center of Disease Control 
(CDC) in USA suggested and published a working case definition of CFS 118, later to 
be revised and replaced by the 1994 CDC case definition 92 (see Appendices, 8.1). In 
this case definition, CFS is defined as an unexplained, persistent or relapsing chronic 
fatigue of new or definite onset; it is not the result of ongoing exertion; it is not 
substantially alleviated by rest; and it results in substantial reduction in previous 
levels of occupational, educational, social or personal activities. Additional 
requirements are the concurrent occurrence of four or more of specified symptoms: 
impairment in short-term memory or concentration, sore throat; tender cervical or 
axillary lymph nodes; muscle pain, multijoint pain without joint swelling or redness; 
headaches, unrefreshing sleep; and postexertional malaise lasting more than 24 hours. 
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Since then, the term Chronic Fatigue Syndrome (CFS) has been accepted as the most 
common term for unexplained, severe chronic fatigue, and the CDC case definition 
has been the most widely used case definition internationally 124,164,257. Still, other 
case definitions of CFS has been suggested and are being used, as the British/ Oxford 
case definition 207 and the Australian case definition 196.  
Despite efforts to reach consensus about case definitions and research criteria and 
resolve ambiguities in the CFS case definitions, interests have been conflicting and 
the discussions are ongoing 125. Advocates of CFIDS and postviral chronic fatigue 
(PVCF) in USA and myalgic encephalomyelitis (ME) in Britain have fought for more 
exclusive case definitions, emphasizing the explicit organicity by infection-
precipitation and the extensively functional impairment beyond fatigue symptoms 
alone 171,210. In 2003, a Canadian group proposed a case definition aiming at 
integrating the wider case definition of CFS and the somewhat stricter concept of 
ME, in a ME/CFS working case definition 38. Although being used in research, it has 
not been recognized as the ultimate solution to an unambiguous case definition 39. 
In 2007, the National Institute for Health and Clinical Excellence (NICE) in London 
published guidelines for diagnosis and management of CFS/ ME, based on a 
consensus work of professionals and patients, in an attempt to provide updated 
clinical recommendations for clinical use 11,165. Although welcomed by most 
professionals as a useful tool in improving diagnosis and management of CFS/ ME 
254, it is still being opposed by some patients, who have made an official lawsuit 
against NICE for a judicial review of the guidelines. 
Like neurasthenia in its time, the contemporary chronic fatigue syndrome certainly is 
an illness of extraordinary controversy and accompanying engagement. 
This thesis deals with a clinical population being defined initially by the wide criteria 
of neurasthenia (ICD-10)265 , which also includes CFS. The possible differentiation 
between neurasthenia and CFS, therefore, is highly relevant for the thesis. Studies 
having compared neurasthenia and CFS show that these diagnoses are overlapping 
and that the clinical populations are comparable 88,114. 
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(See Appendices 8.1: Case definitions, for description of neurasthenia, CFS-CDC and 
CFS-Oxford) 
 
1.1.4 Medical Unexplained Symptoms; pathoplasticity 
As a parallel academic discussion to those of neurasthenia and CFS case definitions, 
the question of labelling the medically unexplained symptoms that persist through all 
revisions of classification systems and case definitions have been raised but not 
resolved. The term Medically Unexplained Symptoms (MUS) has been used 
increasingly, although still debated and explored 12. The validity and stability of the 
term has been challenged 145, and the associations to the diagnosis of somatoform 
disorder, the concepts of alexithymia, somatisation and psychological mechanisms 
have been studied 12,112,141,146,192. Medically unexplained symptoms (MUS) have no 
stringent criteria or case definition, and as a medical term have thus been subject to 
sometimes professionally ambiguous use 166,167 or categorization depending on 
medical speciality 204, although working case definitions have been suggested and 
tested for interrater-reliability 188. An additional aspect of making the diagnosis of 
MUS is the influence of the doctor-patient relationship in the decision-making 166. 
Since CFS by its definition is medically unexplained, it is sometimes included in the 
case definitions of MUS, partly depending on the discretion of the clinician, but most 
often CFS is excluded from MUS, along with Irritable Bowel Syndrome (IBS), 
fibromyalgia and other syndromes with operationalized case definitions. Still, this is a 
gray zone of unresolved dilemmas and borders. Researchers and clinicians have 
called for a comprehensive model and a biopsychosocial approach in analyzing and 
managing the challenges with medically unexplained symptoms 12,29,33,62.  
The term subjective health complaints (SHC) has also been suggested as a useful 
term in describing such unexplained symptoms, assigning no cause or attribution to 
the complaints, which would be a better term than symptoms, implying an underlying 
disease 80,230. 
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Also, the term functional somatic disorders have been used for many of these 
syndromes, including CFS, IBS, fibromyalgia and Multiple Chemical Sensitivity 
(MCS) as well as war syndromes 6,131,134,168,250. One implication of the term has been 
that “functional” disorders essentially represent mainly psychological conflicts or 
disguised psychiatric disorders. This contributes to the scepticism among patients 
towards being labelled “functional”251, and to the dynamics in the medical 
establishment and in the culture of making a diagnosis 131. 
In the classifications systems of ICD-10 and DSM-IV, these “unexplained” 
conditions have been lumped together in undifferentiated categories of “somatoform” 
disorders 5,264, but revision of these classifications are soon to come, based on critical 
analyses of the somatoform and “unexplained” concept 12,37,57,142,145,154,217,224,237. 
Possibly, a new classification system will also bring and facilitate a more 
comprehensive view of these “unexplained” conditions 217. 
Historians of medicine have described a universal “pool” of unexplained symptoms 
or illnesses since ancient times, often referred to as a “psychosomatic pool” 211. These 
illnesses have the characteristics of varying and changing appearances and labels, 
transient explanations and attributions, and often show a characteristic pattern of rise 
and fall in prevalence and popularity. 
This process of fluctuations and change in illness labels and explanations has been 
called “pathoplasticity” – a plasticity in the presenting features of an illness; a 
tendency to illness attribution and illness presentation changing with fashion, media- 
mediated medicine and popular knowledge 211. Such changes are often characterized 
by subjectively based knowledge opposing evidence-based medicine and research. In 
this process, the influence of the media is instrumental, by presenting fragmented 
medical knowledge and by generalizing from the individual and from the subjective 
illness.  
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Through history this process of changing labels, attributing old symptoms to new 
labels and discovering new symptoms once they have been presented and described, 
has been characteristic for several illnesses, mostly within this pool of medical 
unexplained complaints and functional somatic illnesses 250. The symptoms and 
subjective complaints can be varied, often unspecific, and the causes or “attributions” 
seem to move from inner demons to external toxins and invisible waves 211.  The 
modern history of fatigue can be examined in this perspective, perhaps explaining 
some of the mystery and controversy of this illness 244. 
 
The clinical work included in this thesis is a part of this complex history and 
comprehensive context of fatigue illness being described in this chapter. The clinical 
approach and research questions would be different without recognizing the history, 
the ambiguities in classification and the associations to related issues of medically 
unexplained symptoms. Also, it is a fair assumption that knowledge of the historical 
context of fatigue and the recognition of its complexity may contribute to empathic 
attitudes and respect in the clinical research encounter with patients severely disabled 
by chronic fatigue. 
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1.2 Earlier research 
1.2.1 Context of CFS: 
      Diagnosis, prevalence, comorbidity, pathophysiology 
Case defintions of CFS 
Several case definitions for CFS have been presented and are being used in research 
and clinical work. The case definitions generally accepted are the CFS- CDC (Center 
for Disease Control) definition of 1988 118, later  to be revised and replaced by the 
CFS-CDC 1994 case definition 92(see Appendices 8.1); the  British CFS-Oxford case 
definition 207(Appendices 8.1);  the Australian case definition for CFS 196 and the 
Canadian clinical working case definition for ME/CFS 38. There is no general or 
international agreement about which case definition to use or to accept as a “gold 
standard”, although the CFS-CDC (1994) case definition is most widely used and 
most often referred to in research. In a systematic review of the different case 
definitions 164, one conclusion is that no studies have established the superiority of 
one existing case definition over another. The essential characteristics likely to 
distinguish CFS are post-exertional fatigue not alleviated by rest and a cluster of 
symptoms that include chronic fatigue, sore throat, lymph node pain, post-exertional 
malaise, memory/ concentration problems and unrefreshing sleep 127.  These 
characteristic are included in the case definitions. 
There is an ongoing discussion about the case definitions; researchers have pointed to 
the ambiguities of the existing definitions and the need for reclassification 
135,137,186,218; others - including patient groups - have called for  stricter and more 
precise criteria identifying the allegedly specific and most severe subgroup of CFS; 
myalgic encephalomyelitis (encephalopathy) ME 2,38,39,210. However, the current 
position in international research today seems to be the use of the terms CFS and ME 
as synonyms, often as CFS/ME or “CFS, often called ME” 40,43,136,165,181,254. 
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The issues of case definitions are relevant to the studies in this thesis, as the use of 
case definitions will influence the sample selection and possible selection bias. The 
results of the clinical studies will be discussed within the context of differentiating 
the patients with chronic fatigue in clinical subgroups. 
 
Epidemiology 
Many epidemiological studies have been carried out to assess the prevalence of CFS 
16,42,87,114,184,245,273. Most studies share the problem of selection bias by the use of 
different case definitions and inclusion criteria, by examining patients in primary or 
secondary or tertiary care, by community surveys or clinical studies, by the 
inconsistencies in sociodemographic variables like age, gender, ethnicity and 
industrialization, as well as inconsistencies in the inclusion of psychiatric 
comorbidity in the samples. The epidemiological data found in various 
epidemiological studies indicates a prevalence of CFS between 0.2 % - 0.7 % in the 
general population in Europe, Australia and USA 114,153,249. Allowing for psychiatric 
comorbidity, the prevalence of CFS has been shown to be 2.5 % 248. Studies of 
chronic fatigue in samples with varying ethnicity, age, gender, occupational status 
and use of diagnostic criteria have shown high prevalence of chronic fatigue, 
reaching 11-12 % from England 248 to India 184. 
Several studies of chronic fatigue patients in primary care who fulfilled criteria for 
CFS but where neither patients nor doctors were aware of the diagnosis, indicate that 
the patients suffering from CFS probably outnumber and probably have different 
characteristic from those CFS patients who seek referral for establishing/ confirming 
the diagnosis. It also emphasises the role of selection bias in CFS studies 246. 
The question of epidemiology, then, is a complex one, as there is no general 
consensus on methodology and research shows a wide range of results, possibly 
based on a wide spectrum of research quality and wide variation in selection criteria 
of the populations studied. 
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Comorbidity 
Although being defined by specific characteristics, Chronic Fatigue Syndrome is by 
its nature and definition also a syndrome of varied and complex symptomatology, 
showing symptoms from many organ system and subjective complaints of varying 
intensity and duration. When fatigue is clearly accompanying and a secondary 
symptom to a specified medical disorder, it will exclude the diagnosis of CFS, but in 
many cases comorbid illness will exist and cause symptoms of varying intensity. CFS 
has been shown to have high rates of both somatic and psychiatric comorbidity 3, and 
studies have reported strong associations and high degree of overlap between chronic 
fatigue and fibromyalgia, irritable bowel syndrome, chronic pelvic pain, multiple 
chemical sensitivities and temporomandibular disorder, and have reported that 
chronically fatiguing illnesses were associated with high rates of many other clinical 
conditions 274-276. Studies of subjective health complaints in neurasthenia have shown 
high levels of health complaints from all organ systems, exceeding the level found in 
many other chronic illnesses 120. 
The distinction between overlapping conditions based on overlapping case 
definitions/ diagnostic criteria and comorbidity of medically different illnesses can be 
difficult or non-existing 134,202, and some of the research in this field is confusing 
because this distinction is overlooked. Studies show that somatic complaints are 
associated with increased social and psychiatric morbidity 138, without knowing what 
and which illness is primary or secondary 247. The significance of studying temporal 
relationships between comorbid conditions in order to identify and treat illness has 
been emphasized 276. Also, recognizing that generalised fatigue very often can be a 
symptom of other diseases 205, the study of comorbidity will be complex, as the 
“comorbid” condition might be the actual morbus and cause of fatigue.  
The role of psychiatric illness in CFS has been studied and described extensively. 
Depressive and anxiety states seem to be of particular importance in CFS, most 
studies showing a high prevalence and comorbidity with depression, to a lesser extent 
anxiety disorders 3,52,75,93,214,228,247. The role of personality pathology in CFS has been 
given relatively less attention. The research that does exist on this often includes 
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patients without formal CFS diagnosis or with unclear case definitions of chronic 
fatigue syndromes 32,52,110,129,252,260,262. Associations between personality factors and 
fatigue states have been described, particularly associations to neuroticism 219 and 
negative aspects of perfectionism 152.  The combination of higher levels of 
perfectionism, doubts about actions, concern over mistakes and  lower self-esteem 
has been  mentioned as important in the development and perpetuation of chronic 
fatigue 252. The relevance of cognitive assumptions or pre-morbid personality 
characteristics has also been described: conscientiousness, perfectionism and social 
control, creating a coping style making the person vulnerable to exhaustion in 
situations of inadequate competency and emotional control 223. The tendency to 
catastrophizing and exaggerated somatic focus have been shown to be of importance 
in the related illnesses of pain and fibromyalgia 94,109, and catastrophic beliefs have 
been shown to impact on level of functioning in CFS 176.  
Studies of personality disorders in CFS have shown high levels of personality 
disorder (40%) 110. It has been hypothesised that the personalities of CFS patients 
may have been altered by their chronic illness 51. It has also been suggested that any 
link between personality and fatigue states may in part be confounded by depression, 
and when examining personality factors in CFS compared to other chronic and 
disabling illness like Rheumatoid Arthritis (RA), there is no evidence of specific 
personality differences in CFS sufferers 262. 
Research evidence concerning psychiatric comorbidity is thus conflicting, and the 
issue of psychological factors in CFS is one of the most controversial in this field. 
The issue of comorbidity is of great relevance, as it influences the clinical samples 
being studied, by allowing various degrees of comorbidity. Furthermore, the level of 
psychiatric comorbidity have been shown to be a strong predictor for prognosis, 
disability and medical utilisation 114,128,227.  
Further research in this field seems needed. Comorbidity of depression and 
personality disorder is therefore one of the research issues in this thesis. 
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Pathophysiology, immune and neuroendocrine dysfunctions  
The pathophysiology of chronic fatigue syndrome has been an issue of interest since 
the early days of Beard’s Neurasthenia in 1869 17, both among researchers and even 
more intensely in the public discussion and in patient groups. Numerous research 
findings and theories concerning pathophysiology in general and autonomic 
dysfunction (dysautonomia), neuroendocrinological and immunological dysfunctions 
in particular have been presented; some have been disproved, others not being 
replicated; some forgotten, others still alive but with varying evidence to support 
them 3,30,44,53,54,70,73,95,130,140,151,153,173,174,255.  
There is evidence for immunological dysfunctions in CFS, but reviews and 
evaluations of the immunology in CFS have so far concluded that no consistent 
pattern of immunological abnormalities can be identified 50,151,182. Preliminary 
evidence for a subgroup of CFS based on impaired natural immunity has been 
presented 213, using low natural killer cell activity (NCKA) as discriminator between 
subgroups of CFS. Other studies have found significant differences in cytokines and 
interleukins and immune T-cell activity and immune activation 216. Overview reports 
emphasize the growing body of immunological and genomic evidence for immune 
dysregulation in subgroups of CFS, which should result in targeted therapies that 
impact immune function, hypothalamic-pituitary-adrenal axis regulation, and 
persistent viral reactivation 139.  
In the field of neuroendocrinology, the main theory concerning CFS has been a mild 
hypocortisolism of central origin, suggesting an impaired activation of the 
hypothalamic-pituitary-adrenal (HPA) axis 74. Although recent research supports a 
central origin of this disturbance, possibly related to premorbid stress, uncertainties 
remain about the primary or secondary character of the HPA- axis dysregulation. 101. 
Other reports in search of consistent patterns of neuroendocrine pathology in CFS 
concerning cortisol response and pro-inflammatory cytokine response to stress show 
no conclusive evidence 100,103, although offering integrative models of interaction 
between stress, immune processes, proinflammatory cytokines and brain responses, 
including fatigue 60. Dexamethason-suppression-test show increased suppression of 
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cortisol in CFS, indicating enhanced negative feedback of HPA-axis102. Other 
neuroendocrine challenge tests show that some of the HPA-dysregulation could well 
be secondary to behavioural correlates to CFS, like profound inactivity, 
deconditioning and sleep disturbances 99. 
Autonomic dysfunction or dysregulation, referred to as dysautonomia, particularly 
affecting sympathetic activity and homeostatic regulation of the autonomic nervous 
system, has been suggested as a possible pathophysiological mechanism in CFS 96. 
There is a fairly large research body on the association between CFS and neurally 
mediated hypotension as part of the dysautonomias 35. Most findings support an 
association between CFS and dysautonomia, hypothesizing abnormal cardiovascular 
reflexes, neurally mediated hypotension and orthostatic instability as pathogenic 
mechanisms. Results are not consistent; other studies fail to replicate orthostatic 
instability, calling for a reappraisal of primary dysautonomia as essential explanatory 
factors in the pathogenesis of CFS 132. 
In recent Norwegian studies evidence has been presented confirming altered 
sympathetic nerve activity among CFS adolescent patients, supporting the hypotheses 
of sympathetic dysfunction as essential in CFS pathophysiology 268-271. In these 
studies, adolescents with CFS were found to have significant abnormalities of 
cardiovascular regulation in response to mild orthostatic stress, differentiating them 
from healthy controls 268, showing sympathetic predominance of cardiovascular 
regulation during very mild orthostatic stress 270. They seemed to have increased 
sympathetic cardiovascular activity at rest, enhanced sympathetic cardiovascular 
response to orthostatic stress, but attenuated sympathetic cardiovascular response 
when performing isometric exercise during orthostatic stress, suggesting a possible 
causal relation between sympathetic dysfunction, cardiovascular dysregulation and 
patients’ complaints 271. Observations in these studies indicated that adolescent CFS 
patients had abnormal catecholaminergic-dependent thermoregulatory responses both 
at rest and during local skin cooling, supporting a hypothesis of sympathetic 
dysfunction and possibly explaining important clinical symptoms 269. 
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A recent review of the pathophysiology of chronic fatigue syndrome emphasizes the 
evidence for the involvement of the central nervous system, including a 
hyperserotonergic state and hypoactivity of the HPA- axis, but raises the still 
unresolved question of whether these alterations are a cause or consequence of CFS50.  
In summary, it seems fair to conclude that no conclusion has yet been universally 
proven as to the pathophysiology of CFS, neither in terms of causal pathological 
mechanisms nor in terms of the pathology of perpetuated chronic fatigue. In many 
cases of somatic diseases with fatigue as an accompanying feature, chronic fatigue 
can only be distinguished from CFS by its accepted attribution to somatic illness 69.  
Models of sensitization mechanisms have been presented integrating theories of 
pathology, dysfunction, dysregulation and imbalance concerning general 
pathophysiology, as well as integrated with psychophysiology, negative cognitive 
illness perceptions and illness behaviour 24,172. The Cognitive Activation Theory of 
Stress (CATS) from Ursin & Eriksen 234 has been presented particularly relevant for 
somatisation processes, unexplained symptoms and subjective health complaints 
83,232.  (See chapter 1.2.3.) 
A model presented recently in a Norwegian dissertation on CFS in adolescents 
suggests a unifying theory of CFS pathophysiology caused by sustained arousal 267. 
This model deals with both predisposing, precipitating and perpetuating factors in 
CFS 182, and allows for heterogeneity of causal factors, seeing CFS as a common final 
pathway of different genetic, physiological, autonomic, immunological or 
psychological mechanisms. This theory is based on CATS and models of sustained 
arousal, stress mechanisms and sensitization 83,85,86,230,233.  
Models of biopsychosocial dynamics have been called for and suggested by many 
researchers 153,156, based on the need for integrating theories of pathophysiology with 
psychological models such as social learning theory, stress and coping, illness 
cognition, and self-regulation models for explaining more carefully the predisposing, 
precipitating, and perpetuating factors in CFS 62. 
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Sensitization models 
Already Beard in 1869 17 presented theories based on some kind of sensitization in 
the Central Nervous System as a possible – although speculative, as Beard himself 
admitted – mechanism in neurasthenia. Later, several theories of sensitization 
mechanisms have been presented as relevant to this and other related illnesses, both 
concerning physiological mechanisms and cognitive processes 
85,86,156,172,220,230,231,233,239. 
Sensitization is defined as an increased reactivity to stimuli, and the concept has been 
used to describe and explain hypersensitivity reactions to external physical stimuli by 
neural sensitization 19,20. It is also a concept that may be used for more complex 
cognitive functioning involved in fear reactions, anxiety and pain-avoidance 24; the 
concept has been expanded by integrating sensitization of afferent impulses with 
psychological processes, explaining a wider range of “unexplained” responses 230. In 
clinical contexts, the mechanisms of sensitization processes could contribute to the 
understanding of excessive fatigue reactions by this model of increased reactivity and 
amplification in the nervous system, including neuroendocrine, psychophysiological 
and immune systems, as well as in cognitive systems of appraisal and behavioural 
responses. Such sensitization can be thought to result both from infectious/ 
postinfectious/ immunological processes 108, from sustained arousal of any 
physiological system 85,86,233, as well as from sustained cognitive arousal caused by 
rumination and negative assumptions 25,26, health worries and anxiety 27,83,226,234,239. 
This model of sensitization expands earlier theories of somatosensory amplification 
14, which sought to explain the increased sensitivity to somatic sensations in some 
patients with unexplained severity of complaints, their interpretation of such 
sensations amplifying the somatic complaint and the clinical presentation and illness 
behaviour. 
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In a slightly different paradigm of explaining the complex interaction between bodily 
signals, emotions and appraisal of somatic sensation, the concept of interoception 
offers a model for psychosomatic processes, including models of how 
psychophysiological sensitization might amplify interoception of sensations like 
general malaise and fatigue 36,55,56,157,185,258.  In exploring and understanding chronic 
fatigue syndromes, these models seem relevant. 
It is possible that sensitization models can provide a common theory integrating many 
overlapping theories and models, and although not explaining unexplainable illness it 
might be a psychobiological starting point for exploring more detailed mechanisms of 
illness processes and phenomenon not yet understood. 
 
This thesis leans on the models of sensitization in the discussions and interpretations 
of empirical findings in the clinical studies. 
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1.2.2 Health and impairment 
Both chronic fatigue (CF) and CFS are associated with significant disability and 
dysfunction at home and at work. Studies and reviews have demonstrated that the 
burden of chronic fatigue is comparable to other severe, chronic disorders, both in 
terms of subjective experience and functional disability 195. 
The health impairment and total burden of fatigue illness can hardly be measured 
exactly, both because of inconsistent use of inclusion criteria and consequent 
heterogeneous clinical population in most studies, and because burden of illness is in 
the end a subjective experience influenced by vulnerability and stress in the 
individual’s life, independent of illness. Psychosocial support, depression, cognitive 
illness perceptions and catastrophic beliefs all influence the experience of and the 
actual disability in chronic fatigue syndrome 176,227,238. 
Assessing health is in itself complicated, and methodological dilemmas are legio. In 
research literature of chronic fatigue, health impairment is partly assessed by 
functional disability and health-related quality of life, partly by number of comorbid 
diagnosis or clinical syndromes, and sometimes by number of symptoms or 
complaints. There are few comparative studies as to which assessments are most 
accurate or correlate the most. Recent studies have reported that the number of bodily 
symptoms show a linear correlation to health-related quality of life and outcome 123. 
A scoring system for subjective health complaints (SHC)82 have been used to 
measure health complaints both in the general population and in clinical groups, and 
studies have correlated subjective health complaints to functional status and work 
disability 81,104,121. A comparison of subjective health complaints in neurasthenia 
compared to illnesses like Irritable Bowel Syndrome (IBS), Low Back Pain (LBP), 
Whiplash Associated Disorder (WAD) as well as comparing to the general population 
and a population on disability pension has been done 120, showing that patients with 
neurasthenia had greater total load of subjective health complaints than most other 
groups, particularly on “pseudoneurological” symptoms 5, but also on complaints 
from all other organ systems 82. 
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As for occupational disability, research shows fatigue itself to be a strong predictor 
for subsequent work disability 235. In a major systematic review of disability in CFS 
the majority of patients represented in the studies reported employment status to be 
unemployed 195. The evidence suggests that some individuals with CFS have 
cognitive or affective impairments on neuropsychological tests, but results are not 
consistent. Depression of greater severity is associated with unemployment, but no 
other impairment appeared to be consistently associated with disability or work 
outcomes. No specific interventions have been proven to be effective in restoring the 
ability to work. No specific patient characteristics have been identified as best 
predictors of positive employment outcomes in CFS patients. Generally, the 
assessment of disability in CFS is associated with the same limitations as in most 
CFS research, concerning consistent methodology, selection criteria and measures 194. 
Health impairment is closely associated with health-related quality of life, and most 
studies in this field report both on health complaints and quality of life. The 
assessment of health impairment is varying some with the clinical population, but 
shows generally an extreme impairment of health and health-related quality of life 
31,107,113,201,248.  
An additional burden of illness in CFS is the subjective experience of not being taken 
seriously by the physicians and the medical system; the subjective complaints not 
being recognized as a medical illness, the illness being questioned as a psychological 
disorder, or just the experience of being ignored or faced with lack of knowledge or 
competence of CFS. The identities of CFS patients are challenged when the 
legitimacy of their illness is questioned. This significant burden adds to a loss of 
previously established identity and makes the patient more vulnerable than just 
suffering from the symptoms 144. 
We know of no previous Norwegian study examining disability and subjective health 
complaints in patients with chronic fatigue syndrome or reporting long-term outcome 
by health impairment. A Scandinavian study from Denmark 6 of 5 years follow-up 
confirmed earlier research of extensive disability in CFS patients. 
                       Bjarte Stubhaug 42 
The issues of subjective health complaints, health impairment and functional 
disability are important elements of the research in this thesis, both in discussions of 
the characteristics of chronic fatigue syndromes and in assessing outcome and 
improvement.  
 
1.2.3 Treatment and prognosis 
During the last 15 years, an increasing number of studies have examined the effect of 
various treatment interventions in CFS, chronic fatigue and neurasthenia. 
“Neurasthenia” seems to identify and include most patients with CFS 88, and 
“neurasthenia” and “chronic fatigue” are often used synonymously in selection 
criteria or descriptions of clinical populations 114,149,208,266. However, the opposite is 
not true: CFS seems to represent a smaller and more severely impaired group of 
patients. This is to be expected from the case definition; CFS is more specific and 
requires more accompanying symptoms than criteria for neurasthenia, as well as 
requiring functional impairment per se (see Appendices 8.1).  
The effects of treatment and prognosis would thus be expected to vary with the case 
definitions being used for sample selection, as research shows 133. As the definition 
becomes more stringent the prognosis appears to worsen. Systematic reviews of 
effect of different treatment interventions have been published, concerning most 
interventions considered generally acceptable. Conclusions from these reviews are 
the main basis of clinical recommendations for the management of CFS, as have been 
published in many countries 165,169,196. 
Systematic reviews of all interventions for treatment and management of Chronic 
Fatigue Syndrome demonstrate mixed results in effectiveness  43,257. There is a wide 
range of treatment designs and outcome measures, and the data are of too inconsistent 
quality to perform robust meta-analyses. Interventions of graded exercise therapy 
(GET) and cognitive behavioural therapy (CBT) have shown positive results and also 
scored high on validity assessment 65,66,180,189,203. For pharmacological interventions, 
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including antidepressant medication, the overall evidence in CFS has been 
inconclusive, and no systematic effects have been proven 10,43,257. A Norwegian 
systematic review of treatment effects in CFS concluded that only CBT and Graded 
Exercise have shown systematic effects 169. The evidence is often weak, and the most 
severely patients are not examined. These conclusions are very much in line with the 
underlying conclusion in the British NICE-report 11, providing systematic guidelines 
for the management and treatment of CFS/ ME. 
In studies in primary care comparing effect of counselling programs to cognitive 
behavioural therapy, results show that counselling with evidence-based knowledge of 
CFS was as effective as CBT 190 . This is also confirmed by studies showing that 
education and counselling increase and sustain exercise in CFS patients 177,178, also by 
2 years follow-up. CBT seems easier to “sell” to patients, effect of GET and CBT 
seems equal on the least severely fatigued patients, but short-term programs of 3 
months seem to be too short for the most disabled patients 189. 
The present state of research evidence for effective treatment with single 
interventions in chronic fatigue syndromes could be summarized by saying that CBT 
and graded exercise have been found effective, mainly on functional impairment, less 
on fatigue symptoms 43. Evidence is weak, however, and all reviews recommend 
further research, preferably with more homogeneous clinical populations, with 
stringent criteria, and with high quality in methodology, design and assessment. 
Combination treatments, i.e. combining different types of interventions have rarely 
been studied systematically in chronic fatigue syndrome.  
The research evidence suggests that high-quality interventions studies are still 
needed, and that the effect of combination therapy would be of special relevance.  
A combination of interventions is tested in the clinical trial included in this thesis. 
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1.3 Summary of research relevant to the thesis 
 
Patients with chronic fatigue seem to have significantly higher risk of having other 
illnesses and more severe functional disability than most other clinical groups and 
reference populations. The concurrent diagnoses and syndromes in CFS have been 
investigated, but subjective health complaints have not been studied. There is no clear 
evidence whether CFS patients have distinctly specific health complaints, if the 
subjective health complaints are similar to those of other illnesses or the general 
population, or if the health complaints are mainly more of the same… 
The study of health characteristics and subjective health complaints seems relevant. 
Research concerning effective treatments for CFS shows that cognitive-behavioural 
interventions and graded exercise have effect, but evidence has been weak and the 
effects on fatigue, mental and physical function show varying results. Educational 
programs seem to be as effective as the more costly CBT, which can be offered to a 
few patients. Although CFS is an illness with evidently complex aetiology and 
complex pathophysiological processes and with frequently accompanying disorders 
like sleep disturbances and depression, few treatment studies have been done to 
examine combination treatment with different interventions. Comprehensive 
treatment programs combining interventions proven effective have rarely been 
investigated with adequate research quality. 
Illness course and prognosis in CFS have generally been found to be poor, but 
varying. Most patients improve, but few seem to recover. Analysis of improvement 
and illness course in clinical subgroups or by illness characteristics show varying 
results. Few systematic long-term follow-up studies have been done. 
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Studies of comorbidity with psychiatric illness and personality disorders in CFS show 
conflicting results and give reasons to different interpretations, as well as background 
for controversies of psychological or somatic cause of CFS. There is no general 
consensus as to what extent personality disorders or personality factors are of 
importance in chronic fatigue syndromes. Further research seems needed. 
Generally, in research of neurasthenia and chronic fatigue syndromes the questions 
and dilemmas of sample selection and selection bias are unresolved. A wide variety 
of inclusion criteria is being used, sometimes inclusion by discretion; assessments are 
based on subjective reports and complaints without objective findings, and the quality 
of research methods are varying widely, making general interpretations difficult. 
 
In this thesis, it has been a main objective in the clinical studies to adhere to 
recognized research methods of high quality, in order to contribute to further 
evidence-based knowledge in the field of chronic fatigue. It has also been a goal to 
address clinically relevant issues in this field, both issues that need confirming or 
replicating and dark holes that need more knowledge. 
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2. Aims and research questions 
 
Based on earlier research on neurasthenia and Chronic Fatigue Syndrome, these 
problem areas and research issues are identified, constituting the empirical basis for 
the present thesis: 
Research question 1:  
- What are the health characteristics of patients with chronic fatigue in terms of 
general health and subjective health complaints, functional impairment and work 
disability? (paper 1) 
 
Research question 2:  
- Would a comprehensive treatment program combining earlier proven effective 
element have positive effect, and would a combination with an antidepressant 
medication give added effect? (paper 2) 
 
Research question 3:  
- What is the illness course after a systematic treatment intervention, during 1 – 5 
years follow-up? (paper 3) 
 
Research question 4: 
 
- What is the prevalence of personality disorders in our clinical population of CFS, 
and is there a specific pattern of personality factors in CFS, compared to a 
reference population? (paper 4) 
Are there associations between personality factors and long-term improvement?  
(paper 4) 
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3. Methods       
3.1 Material 
In the study of neurasthenia and subjective health complaints (paper 1), patients were 
recruited through a screening process after a systematic distribution of questionnaires 
to all patients in waiting rooms of general practitioners in the local area of Haugesund 
Hospital on the West coast of Norway, urban and rural areas, March – May 1999. 
1075 patients filled in questionnaires on subjective health complaints, neurasthenia, 
coping strategies, together with demographic information, illness history and 
lifestyle. The group of responders was considered to be representative for a normal 
patient population in general practice. Responders, who fulfilled screening criteria of 
neurasthenia and/or scored 2-3 (scale 0-3) on the “tiredness” item on Subjective 
Health Complaints (SHC, see Instruments), were invited to clinical interviews.  Out 
of 1075 total responders, 106 fulfilled screening criteria for neurasthenia. 92/ 106 had 
given consent for further interviews, 16 proved not to fulfil criteria of neurasthenia by 
telephone interview, 6 were unwilling to interviews. 70 patients met for clinical 
interviews for establishing the diagnosis of neurasthenia (ICD-10: F 48.0; see 
Appendices 8.1), bringing referral from their GP. 28 patients fulfilled inclusion 
criteria for the study. Patients were also referred directly from the general 
practitioners (GPs) in the region (total population 90.000) to the psychosomatic 
outpatient clinic, for evaluation of neurasthenia and chronic fatigue syndrome. 44 
patients fulfilled inclusion criteria for the study. 
(See flow chart A /fig 1). 
Hence, the neurasthenia group (paper 1) consisted of two groups of patients: one 
group was selected from the patients having completed the screening questionnaires 
and one group was directly referred to treatment for fatigue from GPs in the area. The 
groups did not differ on most of the demographic or outcome variables. However, the 
group of patients referred for treatment had slightly higher level of education, 
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modestly lower physical fitness, fewer of them did physical exercises regularly and 
they had more weeks of sick leave during the last year (31 versus 18 weeks). 
During the interviews, the diagnosis of neurasthenia was confirmed, and possible 
reasons for exclusion were ruled out. The interviews and the evaluation were based 
on an experienced clinical judgment from one and the same interviewer (BS).  
The group of neurasthenia patients (n=72) later went on to randomization and a 
treatment program (paper 2).  
Fig. 1: Flow chart A 
 
The clinical study population were 72 patients with chronic fatigue complaints, 
fulfilling ICD-10-research criteria of Neurasthenia, F48.0 265. Illness definition was 
operationalized by examining ICD-10 criteria. The included patients satisfied the 
ICD-10-criteria, allowing for mild depressive or anxiety symptoms clinically 
evaluated to be independent of or secondary to fatigue symptoms. The criteria for 
Chronic Fatigue Syndrome, using CDC-criteria and British/Oxford-criteria, 92,207 
were also examined in the included patient population of neurasthenia (n=72). 65/72 
patients fulfilled case definition by British/ Oxford criteria; 29 patients fulfilled CDC- 
case definition. 
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The interviews and assessments were done by SCAN 263 structured interview 
schedules, check-lists for neurasthenia and CFS-case definitions (Appendices, 8.1), in 
addition to medical evaluation and laboratory investigations.  
 
Fig.2: Flow chart B (treatment study) 
 
 
 
 
 
 
 
 
 
 
 
72 patients fulfilled the 24 weeks treatment program (paper 2), (fig 2; flow chart B).  
13 patients had a premature discontinuation; for these patients the data from last 
observation carried forward (LOCF) were used in end-of-treatment analysis.  
All study participants were invited to follow-up investigations; 70 patients (97 %) 
met for follow-up studies at 6 months and 1 year. 58 patients (81 %) responded at 5 
years follow-up (2007) by completing questionnaires, 56 (78 %) completed 
interviews and diagnostic evaluation (paper 3). 
mirtazapine, n = 25 
 
Placebo drug, n =24 CCBT, n = 23 
mirtaz +  CCBT  (25) Placebo + CCBT (24) Mirtazapine (11) Placebo (12) 
Assessment by 24 weeks, after completed trial, n= 72 
 
12 weeks 
 
12 weeks 
6 moths follow-up: treatment as preferred, n = 70 
1 year follow-up: n = 70 
 
5 year follow-up: n = 58 (questionnaires)/ 56 (interviews) 
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62 patients from the study population fulfilling CFS case definitions of CFS- Oxford 
or CFS-CDC (excluding patients with neurasthenia non-CFS) provided data for 
assessment of personality disorders by SCID-II interviews; 53 patients completed the 
Personality Assessment Inventory (PAI) questionnaire, providing data for analysis of 
personality factors (paper 4). The study population was further divided into exclusive 
categories of CFS-CDC (n=28) and CFS-Oxford non-CDC (n=34), for analysis 
purposes. 
 
3.2 Design of clinical trial 
 
Treatment intervention study 
A three-armed randomised clinical trial of mirtazapine medication, placebo drug and 
a comprehensive cognitive treatment program (CCBT) was conducted to investigate 
treatment effect in the patient group with chronic fatigue diagnosed with neurasthenia 
(n=72) and chronic fatigue syndrome (n=65/ 72), at an outpatient specialist 
psychosomatic clinic. The CCBT program was compared to mirtazapine and placebo 
for 12 weeks, followed by a 12 weeks treatment regimen with a mixed crossover- 
combination design. Assessments were done by 12 and 24 weeks.  
The protocols and design adhered to the standards of the CONSORT statement of 
randomised clinical trials 4. 
Follow-up study 
Patients met for interviews and completed questionnaires at 6 months, 1 year and 5 
years after end of treatment program, with no systematic treatment in the follow-up 
period. Symptoms, functional impairment, clinical severity and improvement were 
evaluated by self-report questionnaires, structured interviews and clinical assessment. 
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3.3 Instruments 
Data in paper 1 were collected and measured by a compiled questionnaire consisting 
of Norwegian versions of various questionnaires, covering a broad range of factors 
including demographic variables, physical and psychological variables at work, 
factors related to work organizing and leadership, social support and family 
relationships, and individual coping resources. 
Further data from the clinical study group (n=72) were collected by another compiled 
questionnaire measuring illness perceptions, illness management, illness behaviour 
and coping factors. 
Structured clinical interviews were used for diagnostic assessment;  
SCAN 261 for psychiatric diagnosis and evaluation; SCID-II 90 for evaluation of 
personality disorders. The Personality Assessment Inventory (PAI) 159 were used to 
assess personality factors. Clinical checklists for case definitions of CFS (CFS-CDC; 
CFS- Oxford) were used to assess CFS (see Appendices 8.1).  
For outcome measurements in the clinical trial and follow-up study, both self-
reported questionnaires and clinical assessments were used. The specific 
questionnaires and assessments instruments are described in the following section. 
 
Specific instruments and questionnaires 
 
General health: Subjective health complaints 
Subjective health complaints were measured by the Subjective Health Complaints 
Inventory (SHC) 82, consisting of  29 items on subjective somatic and psychological 
complaints experienced during the last 30 days. This questionnaire has been tested 
and has satisfactory validity and reliability 82. Severity was scored on a four-point 
scale, from 0 – no complaints, to 3 – severe complaints. Five sub scales were 
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computed, allergy (5 items), flu (2 items), musculoskeletal pain (headache, neck pain, 
upper back pain, low back pain, arm pain, shoulder pain, migraine, and leg pain) (8 
items), gastrointestinal problems (heartburn, epigastric discomfort, ulcer/non-ulcer 
dyspepsia, stomach pain, gas discomfort, diarrhoea, and constipation) (7 items), and 
“pseudoneurology” 5 (palpitation, heat flushes, sleep problems, dizziness, anxiety, 
and sadness) (6 items). The SHC has been tested and used in studies of the general 
population, in Low Back Pain, Irritable Bowel Syndrome, Whiplash Associated 
Disorder and other chronic illnesses, as well as in studies of comorbidity and health-
related life quality 104,120-122,229. 
 
Coping: CODE  
Coping was measured by the Instrumental Mastery Oriented Coping Factor from the 
CODE 84 coping and defence questionnaire. The questionnaire has satisfactory 
reliability and validity. Instrumental mastery oriented coping (22 items) (active 
problem solving, avoidance and passive expectancy, and depressive reaction pattern) 
implies an instrumental, active, goal-oriented coping style, with strategies like direct 
intervention, considering different solutions to the problem, and considering the 
problem a challenge 84. To get a high score on this factor, the score on active problem 
solving must be high, and the score on avoidance and passive expectancy and 
depressive reaction pattern must be low. Instrumental mastery oriented coping is the 
coping variable in the demand/coping model 79. 
 
Fatigue  
Fatigue was assessed by the Chalder Fatigue Scale 41; a self-rating scale developed to 
measure severity of physical and mental fatigue. The scale consists of 11-items, being 
rated 0-3 in severity. The scale has been found to be reliable and valid in chronic 
fatigue syndrome, showing a high degree of internal consistency 162. Principal 
components analyses indicated a two-factor solution (physical and mental fatigue) 162. 
Chronic Fatigue Syndrome: health and impairment, treatment and prognosis 55 
Clinical Global Impression  
Clinical Global Impressions (CGI) 98 –dimensions of Severity of Illness (CGI-S) and 
Improvement (CGI-I) were used; rated on a 7-point scale. Severity of illness is rated 
within last week; global improvement is rated since admission to the study. CGI-
Severity was assessed by clinical assessment, CGI-Improvement was based on 
patients’ self-reports. 
Quality of life  
Health related quality of life was measured by the generic health status measure SF-
36 (Short Form 36-items) for health situations during the last 4 weeks 150 . SF-36 is a 
generic QoL scale consisting of 36 items describing eight dimensions 243, aggregated 
to one physical and one mental health component 242. Adjusted SF-36 scores were 
calculated. The mean is 50, and a deviation of ten points from the mean represents 
one standard deviation. 
Illness Perception 
The Revised Illness Perceptions Questionnaire (IPQ-R) 163 was used to measure 
patients' illness perceptions. It has demonstrated good reliability and validity across 
several illness groups and includes eight cognitive dimensions.  
Cardiorespiratory fitness  
Cardiorespiratory fitness was assessed by the Åstrand-Rhyming test  (indirect test of 
maximal oxygen uptake (VO2max) 9; the test was performed on an ergometer bicycle 9. 
Depression  
Depression was assessed by Hamilton Depression Scale 21 items (HAMD-21 ), rating 
symptoms of depression by a 21-item rating scale 105,106, indicating the level of 
depression. 
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Personality Assessment  
A Norwegian version of the Personality Assessment Inventory (PAI)158,160,161 (back 
translation to English approved by Leslie C. Morey and Psychological Assessment 
Resources (PAR)) was used. The Norwegian version had been used in studies of 
cognitive schemas in psychiatric outpatients 119. The Personality Assessment 
Inventory (PAI) is a multiscale inventory that is widely used in clinical settings 161,241. 
PAI is an objective inventory of adult personality that assesses psychopathological 
syndromes 158,160. It consists of 22 scales measured by 344 items. The 22 scales are 
organized into four categories that include validity scales, clinical scales, treatment 
scales and interpersonal scales. Its validity has been tested and compared to MMPI-2, 
showing good validity and producing few invalid profiles 22.  
In assessing specific personality factors relevant to research questions the following 
PAI-scales and subscales were used 161: 
Exaggerated somatic focus: Scale for somatic complaints (PAI-SOM), (subscales 
conversion SOM-C, somatisation SOM-S, health worries SOM-H); Doubts about 
actions, concern over mistakes: anxiety scale, cognitive subscale (ANX-C); Tendency 
to catastrophizing: anxiety scale, affective (ANX-A) and physiological subscale 
(ANX-P); Perfectionism: anxiety-related disorder scale, obsessive-compulsive 
subscale (ARD-O); Low self-esteem: mania scale, grandiosity subscale (MAN-G); 
Inadequate social control: dominance interpersonal scale (DOM); Inadequate 
competency:  depression scale, cognitive subscale (DEP-C). 
 
Structured psychiatric interview and assessment: SCAN  
SCAN (Schedules for Clinical Assessment in Neuropsychiatry)263 was used in the 
diagnostic process in assessing psychiatric disorders and symptoms. SCAN  is a 
structured clinical interview for ICD-10 diagnosis 264; it has  been found to have good 
validity and reliability 1,200. The interviewer was trained in use of SCAN. 
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Assessment of personality disorders: SCID-II  
SCID-II 90 is a structured clinical interview for DSM-IV axis-II diagnosis. The 
instrument has been found to have good validity and test-retest reliability 197,259. The 
interviewers were trained for SCID interviews. 
 
 
Safety assessments (paper 2) 
Safety assessments during the intervention study included a full clinical examination 
prior to inclusion in the trial; spontaneously reported adverse events and 
measurements of vital signs and weight at each scheduled efficacy evaluation, in 
addition to laboratory tests. Adverse events were coded in MedDRA system 28, using 
Preferred Term (PT) as unit of registration. There were defined procedures for 
immediate reporting in case of serious adverse events. 
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3.4 Statistical methods 
SPSS (SPSS inc. Chicago, USA) version 11.5 for MS-Windows was used for the 
statistical analyses in paper 1. ANOVA and binary logistic regression statistics were 
used to analyze differences in subjective health complaints in the two populations of 
general help-seeking population and neurasthenia population. 
Analyses in paper 2 and 3 were done with a mixed model for normally distributed 
continuous data for the outcome measures; using PROC MIXED in SAS for 
Windows, version 8 (paper 2) and 9.1 (paper 3). To account for the repeated 
measures for the individuals, individual were entered in a mixed model for repeated 
measures, with an unstructured covariance structure (paper 2) and an autoregressive 
(AR1) covariance structure (paper 3). Other variables were entered as fixed effects. 
Other analyses were done in SPSS version 13 for Windows (paper 2) and 14.01 
(paper 3).  
Analyses in paper 4 were done with a mixed model for normally distributed 
continuous data for the outcome measures; using SPSS version 14.0 for Windows.  
To account for correlation between the different measures for the individuals, a 
variance component model was used. Other variables were entered as fixed effects. 
Descriptive statistics and other analyses were also done using SPSS.  
3.5 Ethics 
The study was approved by the Regional Ethic Committee and the Norwegian Data 
Inspectorate. The trial was registered with the Norwegian Social Science Data 
Services (NSD) prior to any patient inclusion. All participants had received written 
information about the trial and had given formal consent about participation, 
including new formal consent about the follow-up study.  
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4. Results and summary of the papers 
Paper 1 
Neurasthenia, subjective health complaints and sensitization 
Background: Neurasthenia and chronic fatigue syndromes are prevalent and 
disabling illnesses. There are few studies of general health and comorbidity in these 
patients. 
Objectives: To study general health and health complaints, functional disability and 
coping and illness variables in patents with neurasthenia.   
Methods: Patients (n=997) visiting general practitioners in an area in Western 
Norway completed a battery of questionnaires related to subjective health complaints 
and fatigue. 78 other patients were referred directly to the hospital for neurasthenia. 
After screening the selected sample with questionnaires and interviews, a total of 72 
patients were included as ‘neurasthenia’ patients satisfying the ICD-10 diagnosis. 
These patients were compared with the remaining 1003 patients.  
Results: Patients with neurasthenia had more prevalent and more severe subjective 
health complaints than the reference population of patients. Sickness leave periods 
were significantly longer. Patients with neurasthenia reported low levels of 
instrumental coping and poor physical fitness. The overall high score on subjective 
complaints from all organ systems could indicate a general sensitization of the 
afferent inputs from their psychophysiological systems. The lower level of coping 
could be maintaining ruminating cognitive perceptions. A rumination process may 
maintain the expectancies and the sustained activation, and be part of the 
neurobiological foundation for the sensitization process.  
Having examined health and impairment in patients with chronic fatigue, a clinical 
challenge would be to design and study the effect of treatment interventions. 
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Paper 2 
Cognitive–behavioural therapy v. mirtazapine for chronic fatigue 
and neurasthenia: a randomised placebo-controlled trial 
Background: Single interventions in chronic fatigue syndrome have shown only 
limited effectiveness, with few studies of comprehensive treatment programs. 
Objectives: To examine the effect of a comprehensive cognitive behavioural 
treatment program (CCBT) compared to placebo-controlled mirtazapine medication 
in patients with chronic fatigue, and to study the combined effect of the 
comprehensive treatment program and medication. 
Methods: A three-armed randomised clinical trial of mirtazapine medication, placebo 
drug and a comprehensive cognitive treatment program (CCBT) was conducted to 
investigate treatment effect in a patient group with chronic fatigue diagnosed with 
Neurasthenia (n=72) and Chronic Fatigue Syndrome (CFS, n=65/ 72), referred to a 
specialist clinic. The CCBT program was compared to mirtazapine and placebo for 
12 weeks, followed by a 12 weeks treatment regimen with a mixed crossover- 
combination design. Assessments were done by 12 and 24 weeks, by self-report 
questionnaires and clinical assessments. 
Results: By 12 weeks, treatment effect was significantly better in the group initially 
receiving the comprehensive treatment program (Fatigue Scale (p=0.014); Clinical 
Global Impression (p=0.001)). By 24 weeks, the treatment group initially receiving 
CCBT 12 weeks followed by mirtazapine 12 weeks showed significant improvement, 
compared to other treatment groups (Fatigue Scale (p<0.001) and Clinical Global 
Impression (p=0.002)). Secondary outcome measures showed overall improvement, 
but no significant differences between treatment groups.  
Conclusion: Multimodal interventions with initial cognitive-behavioural therapy, 
body awareness therapy and exercise followed by mirtazapine antidepressant 
medication seem to have positive treatment effects in chronic fatigue syndrome. The 
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findings indicate that initial non-pharmacological “priming” by a cognitive-oriented 
treatment program prior to medication gives the best treatment effect. 
 
The results of a 6 months intervention program showed general improvement on 
fatigue symptoms and severity. Since neurasthenia and CFS represent a chronic 
illness, it seemed of relevance to study the further illness course; if improvement 
continued and whether the long-term illness course differed within the patient group. 
 
 
Paper 3 
Illness course in chronic fatigue syndromes. 
A 5 years follow-up study 
Background: A six months randomized clinical trial in patients with chronic fatigue 
syndrome (CFS) and neurasthenia showed positive effect of a comprehensive 
cognitive-behavioural treatment intervention combined with mirtazapine. There are 
few previous studies of time-limited treatments or studies of long-term course of CFS 
based on different case definitions. 
Objectives: 1) To examine the long-term effect of treatment interventions and 
examine if the initial treatment effects were sustained. 2) To study the illness course 
and diagnostic stability in subgroups of chronic fatigue patients based on different 
case definitions (neurasthenia, CFS-Oxford and CFS-CDC). 
Methods: Patients with chronic fatigue syndrome (CFS) and neurasthenia (n=70) 
were examined by interviews and questionnaires at 6 months, 1 year, and 5 years 
after a systematic treatment program. Fatigue symptoms, clinical severity, health-
related quality of life, subjective health complaints and depression were recorded. 
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Results: Improvement in fatigue symptoms in the treatment period continued during 
the follow-up period, but the difference between treatment groups were not sustained. 
Half of the patients showed a substantial reduction in fatigue symptoms during the 
follow-up period, irrespective of the specific treatment received previously. Patients 
fulfilling the case definition of CFS-CDC reported more debilitating symptoms of 
fatigue and showed poor prognosis, and represented the most consistent group with 
chronic fatigue. Patients on antidepressant medication at 5 years follow-up showed 
the greatest improvement on fatigue symptoms from baseline.  
Sudden onset, severity of fatigue at the initial phase of illness and slow improvement 
predicted a poor prognosis. Diagnoses tended to shift from CFS towards the less 
serious condition of neurasthenia and unspecific fatigue through the follow-up period. 
Conclusion: The specific effects of a time-limited treatment intervention seem to be 
of less importance for the long-term course in CFS than the severity and 
characteristic of the illness itself. Findings confirmed that most patients with chronic 
fatigue syndrome have a substantial improvement over some years, while many 
patients still suffer a severe illness course. Different case definitions of CFS seem to 
represent different parts of a fatigue spectrum; the findings support the assumption 
that CFS-CDC represents a distinct illness entity within the fatigue diagnoses, 
characterized more by global severity, functional impairment and subjective health 
complaints than fatigue symptoms alone Improvement of fatigue and improvement of 
mood seemed significantly associated. 
Improvement in self-reported and clinician-assessed fatigue severity in patients using 
antidepressant medication at 5 years follow-up could indicate that some patients 
benefit from antidepressant medication on fatigue symptoms, irrespective of 
depressive symptoms. Findings suggest that CFS-CDC could represent the most 
consistent subgroup of severe CFS, needing further differentiation. Findings also 
suggest that both chronic fatigue illness and CFS case definitions may represent a 
continuum of fatigue rather than specific subgroups. This supports the argument for 
keeping case definitions for chronic fatigue syndrome wide, as in neurasthenia. 
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Keeping the question of psychiatric comorbidity in mind, concerning possible 
psychological components in CFS, it seemed relevant to study psychiatric symptoms 
and personality pathology. Major psychiatric disorders were ruled out by inclusion 
criteria for the study; other psychiatric symptom were evaluated trough intervention 
trial and follow-up (paper 2, 3). It seemed relevant to examine personality disorders 
and personality factors in the patient group with CFS, comparing results to previous 
research on this issue. 
 
Paper 4 
Personality disorders and personality factors in chronic fatigue syndrome 
Background: The role of personality in CFS has not been studied extensively in CFS; 
previous research show varying and inconsistent results concerning the impact of 
personality factors on predisposition and perpetuation of CFS. 
Objectives: To study the prevalence of personality disorders and patterns of 
personality factors in patients with Chronic Fatigue Syndrome (CFS). 
Methods: Patients with CFS (n=53) were interviewed using SCID-II and fulfilled 
questionnaires of Personality Assessment Inventory (PAI) prior to a treatment 
program. Patients were examined at 5 years follow-up after treatment, recording 
fatigue symptoms and improvement after 5 years by self-reported Fatigue Scale. 
Results: The prevalence of personality disorder was low (13 %), equal to a non-
clinical sample. The mean personality score by PAI was 51 (norm T=50), indicating 
low average personality dysfunctions. The total patient group had a clinical profile 
close to that of somatoform disorder (Coefficient of Fit = .667). There were elevated 
scores of somatisation and health concerns and on subscales of vegetative signs of 
depression, and low scores of self-esteem and perfectionism. Low improvement by 5 
years seemed associated with low levels of perfectionism and high levels of 
vegetative signs of depression. 
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Conclusion: Patients with CFS seem to have personality disorders or pathology equal 
to the average population. CFS patients have a tendency to higher levels of 
somatisation and somatic complaints, more vegetative signs of depression, lower self-
esteem and low level of perfectionism. This could be secondary to the CFS illness, 
possible explained by physiological and cognitive sensitisations processes. Findings 
suggest that bodily sensations are exaggerated and cognitive awareness 
correspondingly low. Somatisation may be a function of a psychobiological 
“sensitisation” and CFS may be a chronic stress disorder, characterised by sustained 
activation. Low levels of perfectionism combined with low levels of self-esteem and 
perception of social control could indicate a state of helplessness and negative 
outcome expectancy that is corresponding well with depression. 
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Summary of results 
Patients with neurasthenia and chronic fatigue had substantially more and more 
severe subjective health complaints than a reference group of average patients in 
primary care. Work disability was higher; sickness leave periods were significantly 
longer.  
Improvement after 3 months treatment intervention in a clinical population of 
neurasthenia and Chronic Fatigue Syndrome (CFS) was significantly better in a group 
receiving a comprehensive treatment program of cognitive-oriented group therapy, 
body-awareness therapy and graded exercise (CCBT), compared to mirtazapine and 
placebo drug. After combining different treatment interventions for additional 3 
months, the treatment group initially receiving CCBT followed by mirtazapine 
showed significantly better improvement by 6 months, compared to other treatment 
groups.  
Improvement in fatigue symptoms continued after the 6 months’ systematic treatment 
interventions, but the differences between the initial treatment groups disappeared. 
Half of the patients showed a substantial reduction in fatigue symptoms during a 5 
years follow-up period, and diagnoses tended to shift from CFS towards neurasthenia 
and unspecific fatigue through the follow-up period. Patients with CFS-CDC 
represented the most consistent diagnostic group, reported more debilitating 
symptoms of fatigue and had a poorer prognosis. Patients on antidepressant 
medication at 5 years follow-up showed the greatest improvement from baseline. 
Sudden onset, initial severity of fatigue and slow improvement predicted a poor 
prognosis.  
Patients with CFS seem to have personality disorders or personality pathology equal 
to the average population, with a personality profile similar to patients with 
somatoform disorder. CFS patients have a tendency to higher levels of somatisation 
and somatic complaints, more vegetative signs of depression, lower self-esteem and 
low level of perfectionism. Low improvement by 5 years seems associated with low 
levels of perfectionism and high levels of vegetative signs of depression. 
                       Bjarte Stubhaug 66 
 
Chronic Fatigue Syndrome: health and impairment, treatment and prognosis 67 
5. Discussion 
5.1 Discussion of results 
Research question 1: What are the health characteristics of patients with 
chronic fatigue in terms of general health and subjective health complaints, 
functional impairment and work disability? (Paper 1) 
The main finding in paper 1 was that patients with neurasthenia (including CFS) had 
substantially more subjective health complaints and more functional and work 
disabilities than the general patient group in GP’s waiting room. This finding 
confirms the view of neurasthenia and chronic fatigue syndrome as a severe and 
incapacitating illness 3,34,182. The comorbidity of symptoms and complaints from all 
organ systems raises the question whether neurasthenia/ CFS is an illness 
characterized by general sensitization of afferent impulses and an increased cognitive 
preoccupation with these sensory inputs 19,24,156,233.  This increased sensitivity and the 
possible sensitisation is discussed further in Paper 4. 
 
Research question 2: Would a comprehensive treatment program combining 
earlier proven effective element have positive effect, and would a combination 
with an antidepressant medication give added effect?  (Paper 2) 
 
Systematic treatment programs for 6 months showed clinically significant positive 
effects in the majority of patients. The lack of any non-treated control group makes it 
difficult to fully evaluate these effects; the improvement found could be caused by 
time and illness course alone. This may be an unreasonable assumption, given the 
fact that most patients had several years’ duration of illness with no substantial 
improvement.  
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A comprehensive cognitive behavioural treatment intervention (CCBT) had 
significant better effect than the antidepressant medication mirtazapine alone or 
placebo. Adding mirtazapine to CCBT had added effect on improvement, and this 
combination showed greater effect than the opposite sequence of intervention 
(mirtazapine followed by CCBT). These findings indicate that the effect of a 
comprehensive intervention program with emphasis on illness perceptions and body 
awareness is clinically effective, and that such a program might have a “priming 
effect” on the compliance and effect of medication. This group of patients has 
generally a sceptical attitude towards psychotropic medication 21,217 and showed an 
unusual level of side effects from medication. Therefore, medication (antidepressants, 
sleep regulating medication) to patients with chronic fatigue should be offered 
following an initial intervention focusing on illness perceptions, body awareness and 
careful exercise. 
 
Research question 3: What is the illness course after a systematic treatment 
intervention, during 1 – 5 years follow-up?  (Paper 3) 
Following the systematic interventions reported in paper 2, half of the patients with 
CFS improved substantially over the 5 years. However, the CFS-CDC subgroup 
seemed to be a more consistent diagnostic group than other subgroups with chronic 
fatigue, with the poorest outcome after 5 years, showing little if any improvement. 
This group also differed from other groups before treatment and had greater severity 
in symptom load and functional impairment. The majority of patients fulfilling the 
CFS-Oxford diagnosis by baseline improved during the 5 years. At the 5 years follow 
up most patients no longer qualified for this diagnosis, but had “moved” to 
neurasthenia or did not fulfil any diagnosis of chronic fatigue. 
Depression symptoms also improved substantially during the follow-up period. The 
prevalence of depression, defined by cutoff levels on Hamilton Depression Scale 111, 
was high at baseline; more than half of the patients had a depression score indicating 
mild clinical depression. At 5 years follow-up only 6 % of patients had this level of 
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depression scores. There was no association between level of depression and fatigue 
illness severity. There was, however, a significant association between improvement 
in fatigue symptoms and reduction of depression scores. Patients using antidepressant 
medication by the 5 years follow-up examination had less fatigue symptoms and less 
functional impairment than patients who did not use antidepressant medication. The 
findings indicate that antidepressant medication could have a positive effect on 
chronic fatigue, independent of depression and antidepressant effect, by effect on 
different levels and mechanisms 123,170. 
The results indicated that the long-term effect of a time-limited intervention program 
is of less importance than specific features of the chronic fatigue illness. These 
features might again represent different subgroups of chronic fatigue syndromes, 
showing different prognosis and potential for treatment effect. The characteristics 
predicting poor outcome and prognosis and low improvement corresponded with the 
subgroup of patients fulfilling the CFS-CDC case definition, with a significantly 
higher frequency of precipitating infections and sudden onset of fatigue illness. 
Although there was variation in baseline and outcome variables also within the CFS-
CDC group, supporting the need for resolving ambiguities in the CDC case definition 
and validity of assessment instruments 218, our findings did support the notion of a 
specific, more disabled and severely ill group of patients within CFS. This seem to be 
a group more congruent with the case definitions of myalgic encephalomyelitis (ME)/ 
CFS 38,39, supporting the call for re-evaluation of the case definitions of chronic 
fatigue syndromes. 
 
                       Bjarte Stubhaug 70 
Research question 4: What is the prevalence of personality disorders in our 
clinical population of CFS, and is there a specific pattern of personality factors 
in CFS, compared to a reference population? - Are there associations between 
personality factors and long-term improvement?  (Paper 4) 
Personality disorders and personality factors were examined in patients fulfilling case 
definitions for chronic fatigue syndrome (CFS) (CFS-CDC and CFS-Oxford). There 
was no evidence of the high prevalence of personality disorders (DSM) and patterns 
of specific personality factors in patients with CFS reported by others 110; the 
prevalence of personality disorders was similar to what has been found in the general 
population. As for specific personality factors, there was no signs of increased levels 
of negative perfectionism or obsessive-compulsive factors, as has been described 
earlier 152,252. However, the CFS patients reported lower self-esteem and lower 
experience of self-assertion and social control. This could be interpreted as a feeling 
of helplessness and negative outcome expectancy, being consistent with a mild level 
of depression. The self-concept cluster was stable, indicating that the moderately 
negative cognitive assumptions about health and helplessness were more state-
dependent of the fatigue illness than trait-dependent of the individual.  
The personality “profile” was similar to a reference group of somatoform disorder. 
The CFS patents had clinically and statistically higher levels of somatisation than the 
average reference population. This may be a function of a psychobiological 
“sensitization”, both by chronic physical complaints and by cognitive processes of 
rumination and perseveration of thoughts and worries about the illness. Intervention 
strategies aiming at increasing body awareness and appraisal of bodily sensations 
could be effective in modifying the tendency to somatisation and health worries. 
The prevalence of depression symptoms, low level of self-esteem and perceived 
social control could be interpreted as secondary to having a severe and long-lasting 
illness like CFS. There were no differences in personality factors between the CFS-
CDC and CFS-Oxford groups, in spite of significantly different severity and illness 
course in these two groups. 
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5.2 Issues in interpretation of results and context of CFS 
The empirical work and results constitute the core research of this thesis, along with 
the discussions of the results in this section. However, there are some issues 
concerning the concept and construction of chronic fatigue syndrome that need to be 
discussed in a broader context beyond the specific research questions and papers. 
These issues pertain to the major objectives of this thesis, concerning health and 
impairment, treatment and prognosis, and deal with aspects of classification and 
sample selection, with the concept of comorbidity and with the pathophysiological 
mechanisms that represent the ambiguities and unexplained questions in this field. 
The question of CFS being a somatic or psychiatric illness also needs being 
discussed, as well as the chronically unexplained questions of chronic fatigue. 
In the following chapters, these issues are discussed and brought into the wider 
interpretation of the empirical research issues and discourse of CFS. 
 
5.2.1 Fatigue classification in the clinical sample 
In the clinical studies in this thesis, it was decided to use neurasthenia (ICD-10: 
F48.0) as the primary selection and inclusion criterion, regardless of whether case 
definitions of CFS were fulfilled. In doing so, we wanted to include patients within 
the spectrum of chronic fatigue illness, but still with defined criteria that could be 
operationalized, as was possible with the ICD-10 diagnosis of neurasthenia, using 
ICD-10 research criteria 265. However, we also assessed if the case definitions for 
CFS-CDC 92 and CFS-Oxford 207 were fulfilled, to be able to analyze and compare 
CFS from neurasthenia, as well as comparing the two clinical populations 
corresponding to the case definitions. For purposes of analysis and differentiation, we 
wanted to compare non-overlapping groups, and thus divided our patient population 
into CFS-CDC, CFS-Oxford non- CDC, and neurasthenia non-CFS. 
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It can be argued that the groups of neurasthenia and CFS-Oxford for this reason 
comprised only the least seriously affected patients, and as such were not 
representative for a clinical population fulfilling this diagnosis/ case definition. 
Although recognizing this, the total analyses could still be seen as representative for 
chronic fatigue patients including CFS patients, since through the intervention trial 
and follow-up study both the total group and the differences between-groups 
consistently have been analyzed, using the exclusive criteria for the subgroups of 
patients. 
It can also be argued that the high prevalence of depression found at baseline in our 
patient population should disqualify for a “real” chronic fatigue syndrome or the 
diagnosis of neurasthenia in many patients. This seems insignificant for the diagnosis 
of CFS, as the level of depression was mild in every case, and the fatigue illness 
could not be explained by depression. The CFS-Oxford case definition states 
explicitly that mood disturbance may be part of the illness, and that occurrence of 
depression does not necessarily exclude the diagnosis 207 (appendices 8.1). As for the 
diagnosis of neurasthenia, although the research criteria excludes the presence of any 
mood or anxiety disorder/ diagnosis in the ICD-10 265 (appendices 8.1), it was 
decided to modify the inclusion criteria to allow for mild depressive or anxiety 
conditions that were clinically evaluated as independent of or  clearly secondary to 
the fatigue illness. Comorbid depressive and anxiety symptoms are the rule rather 
than exception in neurasthenia, and allowing clearly secondary symptoms to fatigue 
would be in accordance with the clinical entity and ICD-10 guidelines for 
neurasthenia 114, allowing mild depression as part of the condition (appendices 8.1).   
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5.2.2 Comorbidity of unexplained  and subjective symptoms   
Patients with CFS and neurasthenia have many health complaints, as the empirical 
results show. This thesis does not elaborate on the issues of classifying and 
differentiating the unexplained medical conditions or complaint-syndromes occurring 
in these patients and in related conditions. Chronic fatigue syndrome CFS is by its 
definition unexplained, and the distinction between CFS and “unexplained/ idiopathic 
chronic fatigue” is at best vague, at worst arbitrary. Still, this distinction is being used 
in research 61,155,187,199,256, implying that CFS is an “explained” illness. A way of 
dealing with this dilemma is the stringent use of operationalized selection criteria, 
although it does not resolve the main problem with the overlapping conditions and 
gray zones.  
In the clinical studies, in the papers and in this thesis the selection criteria used are 
being presented, both for neurasthenia as well as CFS-Oxford and CFS-CDC. 
Subjective health complaints (SHC) were assessed and analyzed as a measurement of 
general health (health complaints) and comorbidity, in the sense of coexisting health 
complaints. Comorbidity of subjective health complaints between neurasthenia/ CFS 
and other specified syndromes has been measured, but was not analyzed or presented 
in these studies 120. As the SHC-items do not correspond directly with diagnostic 
criteria in examining “comorbidity” by medical syndromes or diagnostic entities, an 
analysis of comorbidity with specific diagnoses was not made, and a direct 
comparison with previous studies of “medical” comorbidity was not possible. As 
most of these other previous studies have limited clinical significance since they 
report on overlapping conditions based on overlapping inclusion criteria, the use of 
subjective health complaints (SHC) seems as justified and – it could be argued – 
more relevant and useful in assessing comorbidity, morbidity and health. 
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5.2.3 Health and impairment assessments 
The assessment of health was based on measuring subjective health complaints 
(SHC). This has not been done in other studies of CFS, and makes a comparison of 
health in our clinical population to other CFS population difficult. As SHC have been 
measured both in the general population and in other clinical populations with 
chronic illness, assessment of health and health impairment was possible. The results 
showing extremely high levels of subjective health complaints compared to the 
general population are corresponding well with other studies showing high levels of 
comorbidity and overlapping conditions, supporting earlier evidence that shows CFS 
to be a severe illness with a wide spectrum of severe symptoms 3,34,182.  
Furthermore, the high levels of health complaints from all dimensions of SHC 
(musculoskeletal, gastrointestinal, allergy, flu, “pseudo-neurological”) indicate that 
all physiological systems could be involved, as well as cognitive appraisal 
mechanisms of bodily sensations. This supports the model of chronic fatigue as an 
illness of general sensitization 153,156,233. 
Assessment of functional impairment was based on self-reported functional status by 
SF-36, assessing specific domains of functioning, which in this thesis have been 
analyzed by the dimensions of mental and physical functioning 242. The instrument 
does not cover all aspects of functional impairment or life quality, but has still been 
used widely in comparable clinical studies, making comparison with our studies 
possible. The results showing extremely low levels of physical functioning in CFS-
patients are supported by other studies 31,209,227. The relatively less – but still distinctly 
impaired mental functioning, indicate that mental functions are indeed impaired in 
CFS – especially concentration and perception of memory. However, the physical 
impairment exceeds by far the mental impairment. This could be interpreted as CFS 
primarily being a physical illness, with distinct although less severe mental and 
emotional symptoms, indicating that aspects of brain functions are involved. 
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5.2.4 Sensitization models of CFS 
Although this thesis is based on empirical research and data analysis and the results 
will have their empirical validity of their own, the discussions of the results will need 
referring to theoretical concepts. In this thesis, the models of physiological and 
cognitive sensitization described by Ursin, Eriksen, Overmier and Brosschot 
19,25,86,172,232 are the central context from which the discussions and interpretations of 
chronic fatigue syndrome as an end-state of complex sensitization processes 
originate. These models make possible a common concept of the pathophysiological 
and cognitive mechanisms in CFS, without dismissing related models of 
somatosensory amplification 14, psychobiological perspectives 191 or neuroendocrine 
and immunological theories of pathology 50,53,70,95. Also, the old but revived concept 
of interoception 36,55,157,185 give added value to and expands the model of sensitization. 
In the discussions of the empirical findings in studies and papers 1, 3, 4, the theories 
of sensitization are referred to, representing a possible integrative model for the 
physiological and cognitive hypersensitivity indicated by the empirical results. The 
findings of general and widespread subjective health complaints (paper 1) and the 
association between low self-esteem, low coping and poor improvement (paper 4) are 
interpreted and discussed within the model of sensitization, helplessness (stress) and 
sustained cognitive arousal 24,86,232,239. It can be argued that these models and the 
corresponding interpretations are constructs not validated by the empirical findings, 
and that interpretation beyond the empirical results is speculative. Still, in this field of 
chronic fatigue with varying findings of multi-level pathology, models that can 
integrate different perspectives are called for, both as explanatory models and as a 
reference structure in identifying and formulating issues of new research. 
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It is a general interpretation of the results from the clinical studies in this thesis that 
sensitization processes can be involved in both the immunological and 
neuroendocrine dysfunctions appearing to be common aspects of CFS and in the 
cognitive perception and appraisal processes that seem to be part of the perceived 
severity of the illness.  
 
5.2.5 Somatic, psychiatric or sensitization illness? 
In summary, the empirical findings from the studies in this thesis showed and 
confirmed that chronic fatigue syndrome, whether fulfilling case definitions of CFS 
or the diagnosis of neurasthenia is a severe and incapacitating illness with extensive 
subjective health complaints, severe physical disability and moderate mental 
impairment. There was no evidence of increased psychiatric pathology, personality 
pathology or personality disorders in patients with CFS. Half of the patients had 
moderate levels of depression symptoms, clinically evaluated not to explain the 
fatigue symptoms, which were not associated with level of depression score. 
The results indicate that CFS is a syndrome that can not be explained by psychiatric 
illness or personality disorders. This is in contrast to many other reports of psychiatric 
comorbidity 117,214,247, but is confirmed by other studies 3,67,116. These conflicting 
research findings in CFS are probably due to the inherent problem in the CFS concept 
based on a spectrum of case definitions and selection criteria 126. (The dilemmas of 
sample bias are discussed in chapter 5.4.) 
As the issue of CFS being a physical or psychological illness causes controversies in 
the patient groups and in the public as well as in medical and clinical contexts 
130,182,249, results from this study probably will be interpreted both ways. The 
prevalence of patients with depression scores above cutoff for depression would 
indicate that depression is common in CFS, although level of depression is mild; no 
patients had a major depression. Symptoms of depression and fatigue are partly 
overlapping, which could imply that we are in fact assessing part of the fatigue 
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syndrome when measuring depression score 67. Depressive symptoms in CFS could 
also be secondary to and part of the chronic illness, as is reported in studies of 
depression in chronic illnesses 89,129. As discussed in other chapters in this thesis, the 
findings from the studies in the thesis are taken to support the view that mild 
depression and perceived “stress” (paper 4) are secondary to the fatigue illness and 
not predisposing or explaining factors 116. 
The results from the intervention trial showed that treatment actually might help 
people improve with CFS, which has been hard to prove consistently 43. Our CCBT 
treatment program was based on interventions already proven effective, like CBT 179 
and exercise 77, to which we added counselling and education 48,190 in the cognitive 
approach and body awareness therapy in integrating aspects of self-regulation, 
mindfulness and awareness of bodily sensations, limitations and potentials 143,215. The 
obvious problem in analyzing the effective components of such a comprehensive 
program based on combination of interventions is that that all components are 
integrated and no intervention is subject to explicit analysis. This is a limitation in the 
analysis and interpretation of the study, and a different design with a larger number of 
participants might have resolved this by providing another kind of factor analysis. 
The findings from the study could, however, be taken as an indication that 
comprehensive multimodal treatment programs are more effecive than single 
interventions. 
The findings showing that mirtazapine medication gave added effect to CCBT, 
superior to placebo, could also be interpreted as confirming the psychiatric aspect of 
CFS. The same goes for the finding from the follow-up study, indicating associations 
between improvement in fatigue symptoms, improvement in depression score and use 
of antidepressant medication.  
So, again: somatic or psychological? Does effect of medication prove that the CFS is 
de facto a psychiatric disorder? 
The interpretation is complex, since we have no complete understanding of the 
physiological mechanisms by which mirtazapine and other antidepressants have their 
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effect. Earlier studies of antidepressant therapy in CFS have shown no consistent 
effect 43,169, and there is little reason to interpret the impact of mirtazapine in our 
studies as an antidepressant effect. The drug was chosen mainly because its proven 
positive effect on sleep 7,8 and early reports of positive effect in pain and 
fibromyalgia, which have later been supported 91,198, and because psychotropic drugs 
in these categories have been shown to have effect in many of the overlapping 
conditions to CFS and in medically unexplained symptoms. This could be caused by 
complex effects on the global fatigue illness, including treating comorbid depression 
or anxiety symptoms, inhibition of ascending pain pathways or inhibition of 
prefrontal cortical areas that are responsible for "attention" to noxious stimuli 123,170.  
Such a model of action would fit well with the models of psychophysiological 
sensitization as a possible mechanism in these illnesses 86,232, as well as with 
biopsychosocial models of central sensitization 156 and interoception 36. 
A fair conclusion of these findings concerning questions of psychiatric pathology and 
effect of antidepressant medication would then be that our studies support the 
biopsychosocial models of chronic fatigue syndrome, integrating theories of stress, 
sustained arousal, sensitization and the physical awareness of the mental self 58,59. 
Such a conclusion could be part of an integrative concept of CFS based on 
physiological and psychological sensitization processes. 
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5.2.6 Chronically unexplained questions 
In spite of all research being done within the field of chronic fatigue syndromes, CFS 
and CFS/ ME, some questions still remain unexplained, although the dark territories 
of chronic fatigue are being reduced, as the overview of CFS in this thesis shows. 
Issues of causal mechanisms and pathophysiology, of immunology and 
neuroendocrine substrates, of predisposing, precipitating and perpetuating factors, of 
comorbidity and overlap with psychiatric and somatic illnesses: there is still much to 
learn. Although many researchers of CFS might feel like George Beard (1869):  
 “…I feel assured that it will in time be substantially confirmed by microscopical and 
chemical examinations of those patients  who die in a neurasthenic condition”;  
still, others have called for alternative models in exploring the unexplained questions. 
As much of the research in the field of chronic fatigue and CFS seem inconclusive, 
due to inconsistent use of diagnostic criteria, intervention methodology and outcome 
assessments, suggestions have been made to reconsider many of the concepts of 
fatigue and the research methods in the clinical field of fatigue 69. The attempts to 
make case definitions unambiguous as well as find explicit biologic markers for CFS 
seem yet unattainable. “The lack of a uniform definition of subjective fatigue has 
resulted in little advance beyond what was known about fatigue 100 years ago” (John 
DeLuca, 2005)69. Many researchers of fatigue consider the neural mechanisms of 
fatigue to be essential in developing substantially new knowledge about fatigue and 
chronic fatigue syndromes. The study of such neural mechanisms seems yet to be in 
its infancy.  
An alternative concept for studying and analyzing fatigue has been proposed for more 
sophisticated explanations of CFS: defining fatigue by primary and secondary fatigue 
might be one important step towards better understanding and treatment 249. Primary 
fatigue can be seen as the fatigue resulting from specific biologic mechanisms, either 
in the brain or in the systemic physiological system. Such fatigue could be caused by 
disease activity, HPA-axis abnormalities, tryptophan and serotonin, cytokines or 
comorbid medical conditions (e.g. anemia, hypo-/hyperthyroidism). Studies have 
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demonstrated specific neuropathology in patients with chronic fatigue in neurological 
diseases, and it has been suggested that such “central” fatigue may occur due to a 
failure in the integration of the limbic input and the motor functions within the basal 
ganglia affecting the striatal-thalamic-frontal cortical system 45. A state of pre-
existing relative hypocortisolaemia might sensitise the hypothalamic-pituitary-adrenal 
axis to the development of persistent central fatigue after stress 46, as well as result in 
ion channel dysfunctions in the cell membrane, as is hypothesized as an explanatory 
model for chronic fatigue syndrome 47. Furthermore, there are studies confirming 
explicit brain dysfunction in CFS, related to dysfunctional motor planning 63, as well 
as reduction in gray matter volume linked to physical activity 64. 
These theories of central fatigue could constitute an expanded model of chronic 
fatigue syndrome, by integration of the models of sensitization 20,26,86,232,239 and 
interoception 36,258. A common conclusion from these various theories is that neither 
of them presents conclusive evidence or a defined explanatory model, but all provide 
essential elements to an increasingly comprehensive model of chronic fatigue, as well 
as being guides to future research. 
In the concept of distinguishing fatigue by its potential mechanisms 69, secondary 
fatigue is the fatigue caused by general mechanisms like deconditioning, 
psychological factors (depression, anxiety, illness perception), sleep, pain and stress. 
The implication of defining secondary fatigue would be to search for the underlying 
condition causing fatigue, being it sleep or pain or whatever, and to offer the best 
treatment available. According to a model of primary and secondary fatigue, it will be 
naive to expect even effects of any treatment in chronic fatigue syndrome, as the 
mechanisms underlying the fatigue might be totally different. The unexplained 
question is how to differentiate, in the diagnostic process as well as in therapy.  
We definitely do not know all the answers in this field, but we might be on our way 
to raise and understand the essential questions. 
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5.3 Discussion of methodological issues 
Fatigue and fatigue assessment 
Fatigue is a difficult symptom to assess and measure objectively, as it must include – 
in addition to any “objective” measurement available - the subjective experience of 
the individual. Furthermore, as it is not the fatigue itself but the fatigue illness and the 
chronic fatigue syndrome that is the focus of interest in our studies, assessment of 
fatigue as an indicator of CFS can be problematic. Still we are left with fatigue as the 
core complaint and symptom, and it has been accepted research standard to base the 
assessment of CFS severity mainly on the assessment of fatigue. Several instruments 
and questionnaires have been developed for such assessments, studies testing and 
validating these instruments have been carried out, and recommendations have been 
made in guiding clinicians and researchers in which instrument to use 76.  
In choosing one instrument to another, most researchers have to base their choice on 
evaluations and recommendations from others. In our study, we have chosen the 
Chalder Fatigue Scale 41 as the primary measurement for the assessment of fatigue 
and outcome measurement. It can be argued that other assessment scales can be more 
precise or appropriate in our clinical study population or that more comprehensive 
inventories be used. As shown in the papers in this thesis, the fatigue measurements 
were supplemented by assessment of function, using the Medical Outcome Survey 
Short-Form (SF-36)241, as well as assessing the symptoms listed in the CFS-CDC 92 
and CFS-Oxford 207 case definitions of CFS.  
Also, we have used a used the instrument of Clinical Global Impression (CGI) 98 to 
assess severity and improvement, to expand the total assessment of fatigue. This is in 
line with recent recommendations for identification of CFS in clinical work and 
research 186 . 
In addition, symptoms and score of depression were assessed, by using Hamilton 
depression scale 105, in addition to structured psychiatric interviews of SCAN and 
SCID-II. This seemed relevant in evaluating a qualified differential diagnosis of 
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depression or any other mental disorder, as required by the diagnostic criteria of 
neurasthenia and case definitions of CFS. The Hamilton 21-items depression scale 
(HAMD-21) was used, but only the items corresponding to HAMD-17 were 
analyzed, as the additional/ psychotic items were irrelevant with 0 score in all 
patients. 
Clinical assessment bias 
Some outcome measures (Hamilton depression scale, Clinical Global Impression 
(Severity) were assessed by the clinician (BS) involved in and responsible for the 
treatment interventions. These assessments could be biased, and independent 
assessors should be sought but were unavailable in this actual setting. The dilemma of 
possible assessment bias was sought resolved by correlating CGI assessments to self-
reported CGI-Improvement, showing high correlations (paper 2). 
Operalization of inclusion criteria 
Criteria for diagnosis of neurasthenia were used for inclusion of neurasthenia; case 
definitions (CDC and Oxford) were used as check-lists for inclusion of CFS. These 
are not validated questionnaires, but they represent the criteria for CFS and the use of 
these is considered a sufficient operalization. Added symptom inventories and 
functional assessments have been developed to both validate the inclusion criteria and 
to assess the total burden of the illness 240. In our study, we did not use any such 
instruments, but in future research we would recommend using these. 
Design of the intervention study 
To be able to answer the research question of comparing treatment effects of different 
interventions, a design of a randomised clinical trial (RCT) was chosen 4. The 
specific design of the intervention trial was complex, as discussed in paper 2, which 
also made the interpretation of the results more complicated. Ideally, a control group 
receiving no medication should have been part of the study design, but we decided 
against it for ethical reasons. The statistically significant differences found in the 
study indicate that our findings are of clinical relevance for patients with chronic 
fatigue and CFS.  
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As many research studies in this field have used varying design and exhibit varying 
research quality 10,43,169,257, standardized designs and protocols should be used. In this 
thesis, the standards of the CONSORT statement 4 was used in planning the study, in 
the protocols, in the randomisation process and in the data analysis. 
 
5.4 Sample selection, selection bias 
The question of possible selection bias in recruiting patients to the clinical study is 
complicated, as the dynamics and reasons behind responding and willingness to 
participate are difficult to explore. Any sample based on clinical populations will be 
biased and differ from the general population. In the clinical material in this thesis, 
the patients were recruited both through screening procedures (questionnaires) and by 
referral from GPs to the specialist clinic. Patients from these two groups were 
compared, and did not differ significantly, except for higher education in referred 
group, lower level of physical exercise and physical fitness and longer sick leave. The 
clinical population is then a mixture of referred patients to specialist care and patients 
being selected by a general primary care survey. It can be argued that our study 
population thus neither represents (or could be compared to) clinical populations in 
primary care nor patients in tertiary specialist care. Recognizing this, our clinical 
population could still represent a common group of patients seen in clinical practice, 
and as such our findings would be clinically relevant.    
Also, as both the questionnaires used for screening and the indications for referral 
were based mainly on fatigue symptoms, it could be argued that our sample could be 
biased by fatigue selection, possibly excluding patients with other dominating 
symptoms or with the common but poorly defined malaise feeling typical of CFS 187. 
Such bias would be similar for all sample selections based on screening of fatigue 
symptoms, as most studies are, but could be resolved by using additional instruments 
or procedures to assess the illness and its functional impairments 240. 
In our studies, we did not use such additional instruments, but used screening 
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procedures and operationalized inclusion criteria in accordance with common 
research standards.  
In the RCT intervention study, patients were randomised to different interventions, 
resolving the selection question. In the inclusion process, both neurasthenia and 
chronic fatigue syndrome were used in establishing inclusion criteria. Since the 
overlap between neurasthenia and CFS has been shown to be substantial 88, it seemed 
justified to include both these diagnostic categories in an empirical study of chronic 
fatigue. Also, consistently analyzing the subgroups with neurasthenia and CFS, it was 
possible to differentiate the specific clinical populations with specific illness 
characteristics. 
Our studies have no data from the most severely affected patients or patients confined 
to bed, which obviously leads to a bias of the patient sample, as the most severe part 
of the fatigue spectrum is not included in our clinical population. It can be argued that 
this weakens the general interpretations of our findings, and that the group of severe 
CFS patients being confined to bed because of their illness could comprise an entirely 
different illness than the one we are studying. This is a general problem and weakness 
in most CFS research, as these patients rarely are accessible for research carried out 
in hospital out-patient settings, as our studies and most studies are. 
Follow-up selection bias 
85 % of the patients responded to follow-up invitations and participated in follow-up. 
There was no sign of specific selection bias of the responders or non-responders. 
82 % of the patients fulfilling CFS completed PAI questionnaires (53/65) and are 
included in the analysis of personality factors in CFS (paper 4). There was no sign of 
specific selection bias in the responder sample, by analysis of demographic and 
clinical data. 
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In summary, the issue of selection bias is complex but crucial to the interpretation 
and discussion of the results.  In some aspects, the results in the clinical studies in this 
thesis were different from findings in other research studies, although being 
supported by others. The results showing substantial clinical effect of intervention, 
significant long-term improvement and no psychiatric comorbidity could be an effect 
of the cautiousness in many CFS patients towards a study at a psychosomatic/ 
psychiatric clinic. Also, study participants had to accept the use of “medication”- 
mirtazapine or placebo drug, implicating a “risk” of using antidepressants. Many CFS 
patients feel stigmatized by a possible notion of CFS being related to psychiatry in 
any way, and it is possible that this would influence the recruitment and thus the 
sample selection. How this would influence the clinical profile and severity in the 
sample population could only be speculations. Studies have shown that many of CFS 
patients are particularly sceptical to psychiatry and medication and that negative 
attitudes towards treatment interventions influence treatment outcome negatively 
49,68,217. Possibly, our patient sample had a relatively higher proportion of patients 
being positive or open to treatment in a psychosomatic context including medication, 
influencing treatment attitudes and treatment outcome positively. If so, this could 
influence the results towards better outcome reports. 
A factor of definite selection bias in our clinical population was the requirement that 
patients should meet for consultations at the hospital, being able to participate in two 
group session of 1,5 hours each, the session with body awareness therapy requiring a 
fair level of physical strength and ability to move. By this treatment design and 
inclusion requirements, we did not include the most severely affected patients with 
chronic fatigue syndrome. Quite possibly, this implicates a selection bias that would 
affect the treatment outcome in the study population.  
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6. Conclusions and implications 
• Chronic fatigue syndrome seems to be an illness presenting and representing a 
broad spectrum of subjective complaints and functional impairment, from mild 
cases to severe impairment (paper 1, 2, 3). None of the studies have data from 
the most severely affected patients or patients confined to bed. 
• No significant correlation between mental or psychiatric pathology and 
chronic fatigue syndrome was found, neither in terms of prevalent psychiatric 
symptoms, personality disorders and mental dimensions of functional 
impairment, nor in terms of treatment effect or long-term illness course (paper 
2, 3, 4). 
• Personality factors may be associated with illness behaviour and coping. 
Patients with CFS show higher levels of somatisation and physiological 
depressive equivalents than a non-fatigue reference population. The findings 
indicated that personality factors representing low social control, low skills of 
self-assertion and low levels of perfectionism were associated with the poorest 
improvement through the 5 years follow-period. The findings could both be a 
result of the illness and a predictor of illness course (paper 4). 
• Most patients with chronic fatigue syndrome show improvement through a 6 
months treatment program of combined interventions. A comprehensive 
program of cognitive-behavioural treatment, body awareness therapy and 
individualized graded exercise (CCBT) followed by mirtazapine medication 
seemed to be most effective (paper 2). 
• Long-term effect of specific time-limited interventions seemed hard to prove; 
difference in illness severity and improvement between different treatment 
groups were not sustained. All patients in the study received some form of 
cognitive- educational and body awareness therapy, but the sample size was 
too small to make robust analyses of possible interaction effects between 
specific treatment interventions and subgroups of patients (paper 3). 
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• Long-term course/ follow-up through 5 years showed substantially 
improvement in 50 % of the patients, with a corresponding shift in diagnoses 
from more severe case-definitions of CFS to milder case-definitions or to 
neurasthenia or no fatigue diagnosis (paper 3). 
• Prognosis seems to depend mainly on the initial severity and specific 
characteristics of the fatigue illness, corresponding with the most severe case 
definitions. Sudden onset, initial severity, severity by 1 year and slow recovery 
seemed to predict poor prognosis (paper 3). 
 
 Implications for further research:  
• Treatment programs of long duration (more than 1 year) should be established 
and studied systematically by evidence-based methods; combining 
interventions already proven effective. 
• Antidepressant medication should be used for long-term treatment 
interventions (more than 3 months). 
• Studies investigating differences within the fatigue spectrum, especially 
concerning physiological responses, immunological markers and illness 
perceptions should be designed, as well as studies exploring further the 
possible sensitization processes related to chronic fatigue. 
• The group of severely affected fatigue patient (staying at home/in bed) should 
be examined systematically. Interventions based on continuing care and 
support should also be examined, as well as long term course and prognosis.  
• Novel questions of fatigue should be asked, for direction of research efforts, 
identification of unexplored areas and for the mindfulness of not holding on to 
any fixed theory or eternal truth. 
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8. Appendices 
8.1 Case definitions 
 
CFS-CDC (Centre of Disease Control)92 
Chronic Fatigue Syndrome  
A case of the chronic fatigue syndrome is defined by the presence of the following:  
1) clinically evaluated, unexplained, persistent or relapsing chronic fatigue that is of 
new or definite onset [has not been lifelong]; is not the result of ongoing exertion; is 
not substantially alleviated by rest; and results in substantial reduction in previous 
levels of occupational, educational, social, or personal activities; and  
2) the concurrent occurrence of four or more of the following symptoms, all of which 
must have persisted or recurred during 6 or more consecutive months of illness and 
must not have predated the fatigue: self-reported impairment in short-term memory or 
concentration severe enough to cause substantial reduction in previous levels of 
occupational, educational, social, or personal activities; sore throat; tender cervical or 
axillary lymph nodes; muscle pain, multijoint pain without joint swelling or redness; 
headaches of a new type, pattern, or severity; unrefreshing sleep; and postexertional 
malaise lasting more than 24 hours.  
The method used (for example, a predetermined checklist developed by the 
investigator or spontaneous reporting by the study participant) to establish the 
presence of these and any other symptoms should be specified.  
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Idiopathic Chronic Fatigue  
A case of idiopathic chronic fatigue is defined as clinically evaluated, unexplained 
chronic fatigue that fails to meet criteria for the chronic fatigue syndrome. The 
reasons for failing to meet the criteria should be specified.  
The following conditions do not exclude a patient from the diagnosis of unexplained 
chronic fatigue.  
1. Any condition defined primarily by symptoms that cannot be confirmed by 
diagnostic laboratory tests, including fibromyalgia, anxiety disorders, somatoform 
disorders, nonpsychotic or nonmelancholic depression, neurasthenia, and multiple 
chemical sensitivity disorder.  
2. Any condition under specific treatment sufficient to alleviate all symptoms related 
to that condition and for which the adequacy of treatment has been documented. Such 
conditions include hypothyroidism for which the adequacy of replacement hormone 
has been verified by normal thyroid-stimulating hormone levels or asthma in which 
the adequacy of treatment has been determined by pulmonary function and other 
testing.  
3. Any condition, such as Lyme disease or syphilis, that was treated with definitive 
therapy before development of chronic symptomatic sequelae.  
4. Any isolated and unexplained physical examination finding or laboratory or 
imaging test abnormality that is insufficient to strongly suggest the existence of an 
exclusionary condition. Such conditions include an elevated antinuclear antibody titer 
that is inadequate to strongly support a diagnosis of a discrete connective tissue 
disorder without other laboratory or clinical evidence.  
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CFS- Oxford Guidelines 207 
 
Chronic fatigue syndrome (CFS) 
(a) A syndrome characterized by fatigue as the principal symptom. 
(b) A syndrome of definite onset that is not life-long. 
(c) The fatigue is severe, disabling, and affects physical and mental functioning. 
(d) The symptom of fatigue should have been present for a minimum of 6 months 
during which it was present for more than 50% of the time. 
(e) Other symptoms may be present, particularly myalgia, mood and sleep 
disturbance. 
(f) Certain patients should be excluded from the definition. They include: 
(i) Patients with established medical conditions known to produce chronic 
fatigue (eg severe anaemia). Such patients should be excluded whether the 
medical condition is diagnosed at presentation or only subsequently. All 
patients should have a history and physical examination performed by a 
competent physician. 
 (ii) Patients with a current diagnosis of schizophrenia, manic depressive 
illness, substance abuse, eating disorder or proven organic brain disease. Other 
psychiatric disorders (including depressive illness, anxiety disorders, and 
hyperventilation syndrome) are not necessarily reasons for exclusion. 
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ICD-10: F48.0  Neurasthenia  
Considerable cultural variations occur in the presentation of this disorder, and two 
main types occur, with substantial overlap. In one type, the main feature is a 
complaint of increased fatigue after mental effort, often associated with some 
decrease in occupational performance or coping efficiency in daily tasks. The mental 
fatigability is typically described as an unpleasant intrusion of distracting associations 
or recollections, difficulty in concentrating, and generally inefficient thinking. In the 
other type, the emphasis is on feelings of bodily or physical weakness and exhaustion 
after only minimal effort, accompanied by a feeling of muscular aches and pains and 
inability to relax. In both types a variety of other unpleasant physical feelings is 
common, such as dizziness, tension headaches, and feelings of general instability. 
Worry about decreasing mental and bodily well-being, irritability, anhedonia, and 
varying minor degrees of both depression and anxiety are all common. Sleep is often 
disturbed in its initial and middle phases but hypersomnia may also be prominent.  
Includes: 
Fatigue syndrome  
Excludes: asthenia NOS (R53 ), burn-out (Z73.0 ), malaise and fatigue (R53 ), 
postviral fatigue syndrome (G93.3 ),  psychasthenia (F48.8 )  
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Neurasthenia:  ICD-10 Research Criteria 
A. Either of the following must be present: 
(1) Persistent and distressing complaints of feelings of exhaustion after minor mental 
effort (such as performing or attempting to perform everyday tasks that do not require 
unusual mental effort); 
(2) persistent and distressing complaints of feelings of fatigue and bodily weakness 
after minor physical effort. 
B. At least one of the following symptoms must be present: 
  feelings of muscular aches and pains; dizziness; tension headaches; 
  sleep disturbance; inability to relax; irritability. 
C. The patient must be unable to recover from the symptoms in criterion A (1) or (2) 
by means of rest, relaxation or entertainment 
D. The duration of the disorder is at least 3 months. 
E. Exclusion clause: 
The disorder does not occur in the presence of organic emotionally labile disorder 
(F06.6), postencephalitic syndrome (F07.1), postconcussional syndrome (F07.2), 
mood (affective) disorder (F30-F39), panic disorder (F41.0) or generalized anxiety 
disorder (F41.1) 
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